of,O
the,O
most,O
frequent,O
signs,O
and,O
symptoms,O
among,O
confirmed,O
cases,O
Universidade,O
do,O
Sul,O
de,O
Santa,CITY
Catarina,CITY
.,O
Programa,O
de,O
Ps,O
‐,O
Graduao,O
em,O
Cincias,PERSON
da,PERSON
Sade,PERSON
.,O
Tubaro,ORGANIZATION
SC,ORGANIZATION
.,O
Brazil,COUNTRY
Universidade,O
do,O
Sul,LOCATION
de,LOCATION
Santa,CITY
Catarina,PERSON
.,O
Faculdade,PERSON
de,PERSON
Medicina,PERSON
.,O
Tubaro,LOCATION
.,O
SC,ORGANIZATION
.,O
Brazil,COUNTRY
Objective,O
:,O
to,O
describe,O
the,O
most,O
frequent,O
signs,O
and,O
symptoms,O
of,O
infection,CAUSE_OF_DEATH
by,O
se,O
‐,O
vere,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
publications,O
.,O
Re,O
‐,O
sults,O
:,O
the,O
spectrum,O
of,O
clinical,O
disease,CAUSE_OF_DEATH
was,O
wide,O
;,O
fever,CAUSE_OF_DEATH
.,O
coughing,O
and,O
dyspnea,O
were,O
the,O
most,O
frequent,O
signs,O
/,O
symptoms,O
.,O
however,O
.,O
they,O
may,O
not,O
be,O
present,DATE
.,O
thus,O
hindering,O
case,O
definition,O
;,O
gastroin,O
‐,O
testinal,O
symptoms,O
and,O
loss,O
of,O
taste,O
or,O
smell,O
have,O
been,O
reported,O
among,O
mild,O
cases,O
;,O
dyspnea,O
was,O
frequent,O
among,O
severe,O
and,O
fatal,O
cases,O
.,O
Conclusion,O
:,O
considering,O
the,O
scarcity,O
of,O
diagnostic,O
tests,O
and,O
the,O
diversity,O
of,O
symptoms,O
.,O
health,O
services,O
should,O
use,O
a,O
sen,O
‐,O
sitive,O
case,O
definition,O
.,O
in,O
order,O
to,O
adopt,O
appropriate,O
surveil,O
‐,O
lance,O
.,O
prevention,O
and,O
treatment,O
actions,O
.,O
Betine,PERSON
Pinto,PERSON
Moehlecke,PERSON
Iser,O
‐,O
Av,O
.,O
Jos,PERSON
Accio,PERSON
Moreira,PERSON
.,O
No.,O
787,NUMBER
.,O
Bairro,PERSON
Dehon,PERSON
.,O
Caixa,ORGANIZATION
Postal,ORGANIZATION
370,NUMBER
.,O
Tubaro,LOCATION
.,O
SC,ORGANIZATION
.,O
Brazil,COUNTRY
.,O
Epidemiol,O
.,O
Serv,O
.,O
Saude,PERSON
.,O
Braslia,LOCATION
.,O
29,NUMBER
(,O
3,NUMBER
),O
:,O
e2019354,O
.,O
2020,DATE
Suspected,O
COVID,O
‐,O
19,NUMBER
case,O
definition,O
The,O
coro,O
‐,O
navirus,O
2,NUMBER
pandemic,O
related,O
to,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
.,O
which,O
causes,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
emerged,O
at,O
the,DATE
end,DATE
of,DATE
2019,DATE
in,O
Wuhan,CITY
.,O
Hubei,STATE_OR_PROVINCE
Province,LOCATION
.,O
China,COUNTRY
.,O
and,O
has,O
spread,O
rapidly,O
across,O
all,O
continents,O
.,O
exponentially,O
increas,O
‐,O
ing,O
the,O
number,O
of,O
infected,O
people,O
and,O
causing,O
thousands,O
of,O
deaths,O
worldwide,O
.1,NUMBER
It,O
is,O
estimated,O
that,O
as,O
at,O
April,DATE
26th,DATE
2020,DATE
.,O
more,O
than,O
2.8,NUMBER
million,NUMBER
people,O
had,O
been,O
infected,O
and,O
over,O
193.000,NUMBER
had,O
died,O
from,O
causes,O
related,O
to,O
the,O
disease,CAUSE_OF_DEATH
caused,O
by,O
the,O
novel,O
coron,O
‐,O
avirus,O
(,O
COVID,O
‐,O
19,NUMBER
),O
.2,NUMBER
Given,O
its,O
vast,O
magnitude,O
and,O
the,O
diverse,O
sup,O
‐,O
plies,O
needed,O
to,O
control,O
it,O
.,O
such,O
as,O
availability,O
of,O
diagnostic,O
tests,O
for,O
affected,O
people,O
.,O
combating,O
COVID,O
‐,O
19,NUMBER
has,O
become,O
a,O
chal,O
‐,O
lenge,O
.,O
especially,O
for,O
low,O
and,O
middle,O
‐,O
income,O
countries,O
such,O
as,O
Brazil,COUNTRY
which,O
depend,O
on,O
technologies,O
produced,O
in,O
other,O
countries,O
.3,NUMBER
Assessing,O
clinical,O
signs,O
and,O
symptoms,O
shown,O
by,O
infected,O
people,O
can,O
help,O
establish,O
the,O
healthcare,O
flow,O
and,O
indicate,O
the,O
need,O
to,O
perform,O
confirmatory,O
tests,O
.,O
How,O
can,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
be,O
di,O
‐,O
agnosed,O
or,O
defined,O
.,O
if,O
health,O
centers,O
do,O
not,O
have,O
sufficient,O
lab,O
‐,O
oratory,O
tests,O
available,O
?,O
Moreover,O
.,O
diagnostic,O
tests,O
are,O
intended,O
to,O
be,O
used,O
at,O
specific,O
times,O
of,O
infection,CAUSE_OF_DEATH
and,O
.,O
depending,O
on,O
the,O
stage,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
may,O
not,O
be,O
very,O
accurate,O
.4.5,NUMBER
As,O
such,O
.,O
as,O
‐,O
sessing,O
clinical,O
signs,O
and,O
symptoms,O
shown,O
by,O
infected,O
people,O
can,O
help,O
establish,O
the,O
healthcare,O
flow,O
and,O
indicate,O
the,O
need,O
to,O
per,O
‐,O
form,O
confirmatory,O
tests,O
.6,NUMBER
The,O
objective,O
of,O
this,O
study,O
was,O
to,O
de,O
‐,O
scribe,TITLE
the,O
most,O
frequent,O
signs,O
and,O
symptoms,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infec,O
‐,O
tion,O
.,O
in,O
order,O
to,O
guide,O
case,O
suspicion,O
based,O
on,O
clinical,O
manifes,O
‐,O
tations,O
and,O
to,O
characterize,O
case,O
severity,O
.,O
art,O
of,O
a,O
given,O
sub,O
‐,O
ject,O
and,O
enable,O
more,O
in,O
‐,O
depth,O
discussion,O
.,O
that,O
presented,O
a,O
de,O
‐,O
scription,O
of,O
the,O
clinical,O
picture,O
of,O
the,O
first,ORDINAL
COVID,O
‐,O
19,NUMBER
cases,O
.,O
The,O
searches,O
were,O
based,O
on,O
the,O
following,O
research,O
question,O
:,O
What,O
are,O
the,O
most,O
frequent,O
signs,O
and,O
symptoms,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
?,O
The,O
bibliographic,O
search,O
was,O
performed,O
on,O
the,O
Scopus,O
.,O
medRXiv,O
.,O
MEDLINE,ORGANIZATION
.,O
SciELO,O
and,O
Google,ORGANIZATION
Scholar,TITLE
databases,O
.,O
and,O
it,O
was,O
comple,O
‐,O
mented,O
with,O
a,O
manual,O
search,O
on,O
the,O
lists,O
of,O
references,O
of,O
the,O
pa,O
‐,O
pers,O
selected,O
and,O
also,O
on,O
the,O
Brazilian,ORGANIZATION
Health,ORGANIZATION
Ministry,ORGANIZATION
website,O
.,O
No,O
limitations,O
were,O
set,O
for,O
date,O
.,O
study,O
country,O
or,O
area,O
of,O
knowl,O
‐,O
edge,O
.,O
The,O
following,O
terms,O
were,O
use,O
for,O
the,O
search,O
:,O
Signs,O
.,O
symp,O
‐,O
toms,O
clinical,O
.,O
laboratory,O
.,O
combined,O
with,O
Novel,O
coronavirus,O
Novel,O
coronavirus,O
2019,DATE
.,DATE
2019,DATE
nCoV,O
.,O
COVID,O
‐,O
19,NUMBER
.,O
Wuhan,CITY
coronavirus,O
.,O
Wuhan,CITY
pneumonia,CAUSE_OF_DEATH
and,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
and,O
Portuguese,NATIONALITY
.,O
In,O
situations,O
in,O
which,O
more,O
than,O
one,NUMBER
interest,O
.,O
those,O
with,O
smaller,O
sample,O
sizes,O
and,O
/,O
or,O
which,O
were,O
older,O
were,O
excluded,O
.,O
Most,O
frequent,O
signs,O
and,O
symptoms,O
among,O
confirmed,O
COVID,O
‐,O
19,NUMBER
cases,O
Ten,NUMBER
studies,O
were,O
selected,O
which,O
describe,O
the,O
first,ORDINAL
confirmed,O
COVID,O
‐,O
19,NUMBER
cases,O
and,O
the,O
most,O
common,O
signs,O
and,O
According,O
to,O
the,O
Brazilian,NATIONALITY
Ministry,ORGANIZATION
of,ORGANIZATION
Health,ORGANIZATION
.,O
informa,O
‐,O
tion,O
is,O
still,O
limited,O
for,O
characterizing,O
the,O
spectrum,O
of,O
the,O
clinical,O
disease,CAUSE_OF_DEATH
.,O
The,O
Ministry,O
therefore,O
establishes,O
flu,CAUSE_OF_DEATH
‐,O
like,O
syndrome,O
(,O
FS,O
),O
as,O
being,O
the,O
most,O
common,O
manifestation,O
.,O
this,O
being,O
defined,O
as,O
an,O
acute,O
respiratory,O
clinical,O
picture,O
.,O
characterized,O
by,O
sensation,O
of,O
fever,CAUSE_OF_DEATH
or,O
fever,CAUSE_OF_DEATH
.,O
even,O
if,O
reported,O
.,O
accompanied,O
by,O
coughing,O
.,O
sore,O
throat,O
or,O
runny,O
nose,O
or,O
difficulty,O
in,O
breathing,O
.7,NUMBER
If,O
breathing,O
difficulties,O
are,O
present,DATE
.,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
may,O
be,O
considered,O
.8,NUMBER
defined,O
by,O
FS,O
showing,O
dysp,O
‐,O
nea,O
/,O
breathing,O
discomfort,O
or,O
persistent,O
pressure,O
in,O
the,O
thorax,O
or,O
O2,O
saturation,O
below,O
95,PERCENT
%,PERCENT
in,O
ambient,O
air,O
or,O
lips,O
or,O
face,O
with,O
a,O
bluish,O
color,O
.9,NUMBER
According,O
to,O
the,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
(,O
WHO,O
),O
.2,O
the,O
initial,O
signs,O
/,O
symptoms,O
of,O
the,O
disease,CAUSE_OF_DEATH
appear,O
like,O
those,O
of,O
influenza,CAUSE_OF_DEATH
.,O
but,O
vary,O
from,O
person,O
to,O
person,O
.,O
and,O
can,O
be,O
mild,O
.,O
in,O
the,O
form,O
of,O
pneumonia,CAUSE_OF_DEATH
.,O
severe,O
pneumonia,CAUSE_OF_DEATH
and,O
SARS,O
.,O
The,O
majority,O
of,O
infected,O
people,O
have,O
the,O
mild,O
form,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
with,O
symptoms,O
such,O
as,O
malaise,O
.,O
Epidemiol,PERSON
.,O
Serv,O
.,O
Saude,PERSON
.,O
Braslia,LOCATION
.,O
29,NUMBER
(,O
3,NUMBER
),O
:,O
e2020233,O
.,O
2020,DATE
RT,O
‐,O
PCR,O
for,O
RT,O
‐,O
PCR,O
+,O
for,O
Retrospective,O
series,O
with,O
69,NUMBER
cases,O
hospitalized,O
at,O
the,O
Union,CITY
Hospital,LOCATION
.,O
in,O
Wuhan,CITY
.,O
between,O
January,DATE
16,DATE
Retrospective,O
series,O
of,O
214,NUMBER
hospitalized,O
cases,O
;,O
data,O
retrieved,O
from,O
medical,O
records,O
Wang,PERSON
Z,PERSON
et,O
al.,O
.,O
Mao,PERSON
L,PERSON
et,O
al.,O
.,O
Series,O
with,O
24,NUMBER
cases,O
RT,O
‐,O
PCR,O
+,O
for,O
18,DURATION
years,DURATION
old,DURATION
hospitali,O
‐,O
COVID,O
‐,O
19,NUMBER
zed,O
in,O
ITU,O
Bhatraju,O
PK,O
et,O
RT,O
‐,O
PCR,O
+,O
for,O
Retrospective,O
case,O
series,O
.,O
that,O
(,O
i,O
),O
died,O
(,O
n,O
=,O
113,NUMBER
),O
and,O
(,O
ii,O
),O
that,O
Chen,PERSON
T,O
et,O
al.,O
.,O
Symptoms,O
such,O
as,O
diar,O
‐,O
rhea,O
.,O
nausea,O
.,O
vomiting,O
and,O
headache,O
were,O
present,DATE
;,O
32,PERCENT
%,PERCENT
of,O
total,O
cases,O
and,O
38,PERCENT
%,PERCENT
of,O
cases,O
admitted,O
to,O
ITU,ORGANIZATION
had,O
comorbidities,O
.,O
of,O
which,O
diabetes,CAUSE_OF_DEATH
was,O
the,O
most,O
common,O
(,O
20,PERCENT
%,PERCENT
),O
.,O
All,O
cases,O
had,O
pneumo,O
‐,O
nia,O
.,O
98,PERCENT
%,PERCENT
bilateral,O
.,O
Fever,CAUSE_OF_DEATH
(,O
98,PERCENT
%,PERCENT
),O
+,O
coughing,O
(,O
76,PERCENT
%,PERCENT
),O
+,O
myalgia,O
/,O
fa,O
‐,O
tigue,O
(,O
44,PERCENT
%,PERCENT
),O
.,O
dyspnea,O
(,O
55,PERCENT
%,PERCENT
),O
.,O
sputum,O
production,O
(,O
28,PERCENT
%,PERCENT
),O
.,O
headache,O
(,O
8,PERCENT
%,PERCENT
),O
.,O
(,O
5,PERCENT
%,PERCENT
),O
and,O
Coughing,O
(,O
67.8,PERCENT
%,PERCENT
),O
+,O
fever,CAUSE_OF_DEATH
(,O
43.8,PERCENT
%,PERCENT
at,O
15,PERCENT
%,PERCENT
had,O
the,O
se,O
‐,O
vere,O
form,O
of,O
the,O
disease,CAUSE_OF_DEATH
;,O
23.7,PERCENT
%,PERCENT
had,O
at,O
least,O
one,NUMBER
admission,O
and,O
88.7,PERCENT
%,PERCENT
during,O
hospitalization,O
),O
comorbidity,O
(,O
38,PERCENT
%,PERCENT
of,O
severe,O
cases,O
),O
.,O
Common,O
symptoms,O
All,O
14,NUMBER
deaths,O
(,O
20,PERCENT
%,PERCENT
),O
had,O
saturation,O
90,PERCENT
%,PERCENT
.,O
were,O
old,O
‐,O
er,O
(,O
70.5,DURATION
years,DURATION
vs,O
37,DURATION
years,DURATION
),O
.,O
had,O
more,O
comorbidities,O
(,O
hypertension,CAUSE_OF_DEATH
36,PERCENT
%,PERCENT
vs,O
7,PERCENT
%,PERCENT
),O
.,O
cardiovascular,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
(,O
36,PERCENT
%,PERCENT
vs,O
5,PERCENT
%,PERCENT
),O
and,O
diabetes,CAUSE_OF_DEATH
(,O
43,PERCENT
%,PERCENT
vs,O
2,PERCENT
%,PERCENT
),O
.,O
and,O
increased,O
inflammatory,O
cytokines,O
.,O
Severe,O
cases,O
were,O
older,O
(,O
58.7,NUMBER
15.0,DURATION
years,DURATION
vs,O
48.9,NUMBER
14.7,DURATION
years,DURATION
),O
.,O
had,O
more,O
comorbidi,O
‐,O
ties,O
(,O
42,NUMBER
[,O
47.7,PERCENT
%,PERCENT
],O
vs,O
41,NUMBER
[,O
32.5,PERCENT
%,PERCENT
],O
),O
.,O
hyperInflammatory,O
response,O
pat,O
‐,O
Fever,CAUSE_OF_DEATH
tension,O
(,O
32,NUMBER
[,O
36.4,PERCENT
%,PERCENT
],O
vs,O
19,NUMBER
[,O
15.1,PERCENT
%,PERCENT
],O
),O
.,O
and,O
had,O
fewer,O
symptoms,O
tern,O
.,O
principally,O
in,O
severe,O
cases,O
:,O
and,O
anorexia,CAUSE_OF_DEATH
(,O
68,NUMBER
[,O
31.8,PERCENT
%,PERCENT
],O
),O
.,O
CNS,O
:,O
dizziness,O
considered,O
typical,O
such,O
as,O
fever,CAUSE_OF_DEATH
(,O
40,NUMBER
[,O
45.5,PERCENT
%,PERCENT
],O
vs92,O
[,O
73,PERCENT
%,PERCENT
],O
),O
and,O
more,O
leukocytes,O
and,O
neutro,O
(,O
16.8,PERCENT
%,PERCENT
),O
and,O
headache,O
(,O
13.1,PERCENT
%,PERCENT
),O
.,O
PNS,O
:,O
anos,O
‐,O
coughing,O
(,O
30,NUMBER
[,O
34.1,PERCENT
%,PERCENT
],O
vs,O
77,NUMBER
[,O
61.1,PERCENT
%,PERCENT
],O
),O
.,O
Severe,O
cases,O
presented,O
phils,O
.,O
fewer,O
lymphocytes,O
and,O
mia,O
(,O
5.1,PERCENT
%,PERCENT
),O
and,O
ageu,O
‐,O
sia,O
(,O
5.6,PERCENT
%,PERCENT
),O
damage,O
to,O
liver,O
.,O
kidneys,O
and,O
muscles,O
.,O
NS,STATE_OR_PROVINCE
symptoms,O
were,O
more,O
higher,O
CRP,ORGANIZATION
levels,O
common,O
in,O
severe,O
cases,O
.,O
but,O
with,O
no,O
labo,O
‐,O
ratory,O
differences,O
between,O
those,O
who,O
did,O
or,O
did,O
not,O
have,O
PNS,O
symptoms,O
.,O
to,O
be,O
continue,O
Reduction,O
in,O
neutrophils,O
(,O
39,PERCENT
%,PERCENT
),O
.,O
eosinophils,O
(,O
72,PERCENT
%,PERCENT
),O
and,O
lym,O
(,O
87,PERCENT
%,PERCENT
),O
.,O
coughing,O
(,O
55,PERCENT
%,PERCENT
),O
.,O
fatigue,O
(,O
42,PERCENT
%,PERCENT
),O
.,O
phocytes,O
;,O
lymphopenia,O
(,O
42,PERCENT
%,PERCENT
),O
.,O
Fever,CAUSE_OF_DEATH
higher,O
among,O
deaths,O
(,O
79,PERCENT
%,PERCENT
63,PERCENT
%,PERCENT
of,O
cases,O
that,O
died,O
and,O
39,PERCENT
%,PERCENT
of,O
those,O
that,O
recovered,O
had,O
at,O
least,O
one,NUMBER
chronic,O
disease,CAUSE_OF_DEATH
:,O
hypertension,CAUSE_OF_DEATH
(,O
48,PERCENT
%,PERCENT
),O
.,O
cardiovascular,O
Lymphope,O
‐,O
nia,O
in,O
39,PERCENT
%,PERCENT
of,O
deaths,O
Fever,CAUSE_OF_DEATH
(,O
~,O
90,PERCENT
%,PERCENT
),O
+,O
coughing,O
(,O
~,O
66,NUMBER
‐,O
70,PERCENT
%,PERCENT
),O
+,O
diseases,CAUSE_OF_DEATH
(,O
14,PERCENT
%,PERCENT
),O
and,O
cerebrovascular,O
diseases,CAUSE_OF_DEATH
(,O
4,PERCENT
%,PERCENT
),O
.,O
Deaths,O
and,O
5,PERCENT
%,PERCENT
of,O
recov,O
‐,O
ered,O
and,O
milder,O
symptoms,O
;,O
dyspnea,O
and,O
tight,O
chest,O
presented,O
tachycardia,O
(,O
50,PERCENT
%,PERCENT
),O
and,O
tachypnea,O
(,O
27,PERCENT
%,PERCENT
),O
.,O
and,O
satuleukocytosis,O
in,O
50,PERCENT
%,PERCENT
of,O
deaths,O
more,O
common,O
among,O
deaths,O
.,O
as,O
well,O
as,O
loss,O
ration,O
93,PERCENT
%,PERCENT
(,O
64,PERCENT
%,PERCENT
),O
;,O
8,PERCENT
%,PERCENT
of,O
cases,O
that,O
died,O
and,O
10,PERCENT
%,PERCENT
of,O
those,O
and,O
4,PERCENT
%,PERCENT
of,O
re,O
‐,O
covered,O
of,O
consciousness,O
that,O
recovered,O
did,O
not,O
have,O
fever,CAUSE_OF_DEATH
.,O
but,O
did,O
have,O
fatigue,O
(,O
~,O
50,PERCENT
%,PERCENT
),O
.,O
coughing,O
(,O
68,PERCENT
%,PERCENT
),O
.,O
dyspnea,O
(,O
44,PERCENT
%,PERCENT
),O
.,O
myalgia,O
(,O
22,PERCENT
%,PERCENT
),O
or,O
diarrhea,O
(,O
28,PERCENT
%,PERCENT
),O
as,O
initial,O
symptoms,O
.,O
Dyspnea,PERSON
and,O
cough,O
‐,O
ing,O
(,O
88,PERCENT
%,PERCENT
),O
+,O
fever,CAUSE_OF_DEATH
58,PERCENT
%,PERCENT
had,O
diabetes,CAUSE_OF_DEATH
and,O
14,PERCENT
%,PERCENT
had,O
asthma,CAUSE_OF_DEATH
and,O
the,O
disease,CAUSE_OF_DEATH
was,O
75,PERCENT
%,PERCENT
lymphopenia,O
and,O
search,O
(,O
50,PERCENT
%,PERCENT
),O
;,O
sputum,O
production,O
(,O
42,PERCENT
%,PERCENT
),O
.,O
rhinorwith,O
use,O
of,O
glucocorticoids,O
;,O
22,PERCENT
%,PERCENT
were,O
smokers,O
;,O
for,O
other,O
pathogens,O
rhea,O
(,O
17,PERCENT
%,PERCENT
),O
.,O
sore,O
throat,O
(,O
8,PERCENT
%,PERCENT
),O
and,O
headache,O
exacer,O
‐,O
bated,O
than,O
one,NUMBER
chronic,O
condition,O
.,O
Cohorta,O
of,O
1.099,NUMBER
cases,O
RT,O
‐,O
PCR,O
+,O
for,O
from,O
552,NUMBER
hospitals,O
in,O
30,NUMBER
COVID,O
‐,O
19,NUMBER
Guan,O
WJ,O
et,O
al.,O
.,O
Laboratory,O
test,O
Leukopenia,LOCATION
(,O
25,PERCENT
%,PERCENT
),O
and,O
Seriesa,O
comprised,O
of,O
41,NUMBER
cases,O
hospital,O
‐,O
ized,O
as,O
at,O
Huang,PERSON
et,O
al.,O
.,O
RT,O
‐,O
PCR,O
+,O
for,O
Type,O
of,O
study,O
and,O
Place,O
of,O
Betine,PERSON
Pinto,PERSON
Moehlecke,PERSON
Iser,PERSON
et,O
al,O
.,O
Epidemiol,O
.,O
Serv,O
.,O
Saude,PERSON
.,O
Braslia,PERSON
.,O
29,NUMBER
(,O
3,NUMBER
),O
:,O
e2020233,O
.,O
2020,DATE
Place,O
of,O
RT,O
‐,O
PCR,O
:,O
reverse,O
transcrip,O
‐,O
tion,O
polymerase,O
chain,O
reaction,O
.,O
COVID,O
‐,O
19,NUMBER
:,O
disease,CAUSE_OF_DEATH
caused,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
ITU,O
:,O
intensive,O
therapy,O
unit,O
.,O
CRP,O
:,O
C,O
‐,O
reactive,O
pro,O
‐,O
tein,O
.,O
CNS,O
:,O
central,O
nervous,O
system,O
.,O
PNS,O
:,O
peripheral,O
nervous,O
sys,O
‐,O
tem,O
.,O
NS,STATE_OR_PROVINCE
:,O
nervous,O
system,O
.,O
IQR,O
:,O
interquartile,O
range,O
.,O
AST,O
:,O
aspar,O
‐,O
tate,O
aminotransferase,O
enzyme,O
.,O
ALT,O
:,O
alanine,O
aminotransferase,O
en,O
‐,O
zyme,O
.,O
GI,O
:,O
gastrointestinal,O
.,O
vs,O
:,O
versus,O
.,O
Jin,PERSON
X,PERSON
et,O
al.,O
.,O
RT,O
‐,O
PCR,O
for,O
Not,O
reported,O
Retrospective,O
study,O
with,O
651,NUMBER
hospitalized,O
Zhe,O
‐,O
jiang,O
.,O
cases,O
and,O
clinical,O
/,O
epi,O
‐,O
RT,O
‐,O
PCR,O
+,O
for,O
demiological,O
analysis,O
of,O
COVID,O
‐,O
19,NUMBER
74,NUMBER
cases,O
with,O
digestive,O
Cross,O
‐,O
sectional,O
study,O
:,O
204,NUMBER
hospitalized,O
cases,O
Brief,O
communication,O
:,O
Not,O
reported,O
Type,O
of,O
study,O
and,O
Cross,O
‐,O
sectional,O
study,O
with,O
88,NUMBER
hospitalized,O
cases,O
;,O
59,NUMBER
interviewed,O
Pan,O
L,O
et,O
al.,O
.,O
Vaira,PERSON
LA,PERSON
et,O
al.,O
.,O
Giacomelli,PERSON
A,O
et,O
Milan,CITY
.,O
Increased,O
AST,ORGANIZATION
and,O
ALT,O
in,O
the,O
group,O
of,O
patients,O
with,O
ALT,O
(,O
20.4,PERCENT
%,PERCENT
),O
and,O
AST,O
(,O
16.5,PERCENT
%,PERCENT
),O
digestive,O
symptoms,O
.,O
compared,O
to,O
the,O
group,O
with,O
no,O
ALT,O
(,O
5.9,PERCENT
%,PERCENT
),O
and,O
AST,O
(,O
5.0,PERCENT
%,PERCENT
),O
digestive,O
Increase,O
in,O
AST,ORGANIZATION
isolated,O
in,O
patients,O
with,O
GI,O
symptoms,O
greater,O
than,O
in,O
those,O
with,O
no,O
GI,O
symp,O
‐,O
toms,O
(,O
29.35,NUMBER
vs,O
24.4,NUMBER
),O
.,O
No,O
significant,O
different,O
in,O
makers,O
related,O
to,O
CRP,ORGANIZATION
infection,CAUSE_OF_DEATH
and,O
Not,O
reported,O
Not,O
reported,O
Laboratory,O
test,O
Digestive,O
symptoms,O
(,O
diarrhea,O
.,O
vomiting,O
.,O
nausea,O
),O
in,O
11.4,PERCENT
%,PERCENT
of,O
total,O
cases,O
.,O
Fever,CAUSE_OF_DEATH
(,O
85.54,PERCENT
%,PERCENT
),O
.,O
coughing,O
(,O
71.62,PERCENT
%,PERCENT
),O
.,O
sputum,O
(,O
39.19,PERCENT
%,PERCENT
),O
.,O
fa,O
‐,O
tigue,O
(,O
31.08,PERCENT
%,PERCENT
),O
and,O
headache,O
50.5,PERCENT
%,PERCENT
of,O
hospitalized,O
patients,O
had,O
digestive,O
symptoms,O
:,O
loss,O
of,O
appetite,O
(,O
78.64,PERCENT
%,PERCENT
),O
.,O
diarrhea,O
(,O
34,PERCENT
%,PERCENT
),O
and,O
vomiting,O
(,O
3.9,PERCENT
%,PERCENT
),O
.,O
Concomitantly,O
.,O
94,PERCENT
%,PERCENT
had,O
respiratory,O
symptoms,O
:,O
fever,CAUSE_OF_DEATH
(,O
92.23,PERCENT
%,PERCENT
),O
and,O
Retrospective,O
study,O
.,O
Chronic,O
liver,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
rate,O
was,O
higher,O
in,O
cases,O
with,O
GI,O
symptoms,O
in,O
relation,O
to,O
those,O
with,O
no,O
GI,O
symptoms,O
(,O
10.81,PERCENT
%,PERCENT
vs,O
2.95,PERCENT
%,PERCENT
),O
.,O
Severe,O
/,O
critical,O
type,O
rate,O
was,O
greater,O
in,O
cases,O
with,O
GI,O
symptoms,O
than,O
in,O
those,O
without,O
symp,O
‐,O
toms,O
Descriptive,O
.,O
cross,O
‐,O
section,O
and,O
multicenter,O
study,O
.,O
Cases,O
with,O
digestive,O
symptoms,O
had,O
longer,O
hospitalization,O
time,O
in,O
relation,O
to,O
patients,O
without,O
digestive,O
symptoms,O
(,O
9,DURATION
days,DURATION
vs,O
7.3,DURATION
days,DURATION
),O
.,O
Howev,O
‐,O
er,O
.,O
there,O
was,O
no,O
significant,O
difference,O
in,O
the,O
time,O
of,O
hospital,O
discharge,O
.,O
days,DURATION
in,O
ITU,ORGANIZATION
or,O
mortality,O
between,O
the,O
groups,O
.,O
Fever,CAUSE_OF_DEATH
(,O
72.8,PERCENT
%,PERCENT
),O
.,O
coughing,O
(,O
37.3,PERCENT
%,PERCENT
),O
.,O
dyspnea,O
Symptoms,O
appeared,O
more,O
in,O
wom,O
‐,O
en,O
(,O
52.6,PERCENT
%,PERCENT
vs,O
25,PERCENT
%,PERCENT
),O
and,O
(,O
25.4,PERCENT
%,PERCENT
),O
.,O
arthralgia,O
(,O
5.1,PERCENT
%,PERCENT
),O
.,O
at,O
least,O
one,NUMBER
smell,O
younger,O
people,O
(,O
median,O
56,DURATION
years,DURATION
.,O
IQR,O
47,NUMBER
‐,O
60,DURATION
years,DURATION
vs,O
66,NUMBER
years,DURATION
.,O
or,O
taste,O
sense,O
disorder,O
(,O
33.9,PERCENT
%,PERCENT
),O
or,O
both,O
IQR,O
52,NUMBER
‐,O
77,NUMBER
),O
.,O
72.8,PERCENT
%,PERCENT
had,O
pneumonia,CAUSE_OF_DEATH
at,O
hospital,O
admission,O
.,O
Anosmia,O
and,O
ageusia,O
associ,O
‐,O
ated,O
with,O
fever,CAUSE_OF_DEATH
.,O
Some,O
kind,O
of,O
dysfunction,O
:,O
19.4,PERCENT
%,PERCENT
(,O
not,O
accompa,O
‐,O
nied,O
by,O
nasal,O
obstruction,O
or,O
rhinitis,O
Common,O
symptoms,O
Suspected,O
COVID,O
‐,O
19,NUMBER
case,O
definition,O
Epidemiol,O
.,O
Serv,O
.,O
Saude,PERSON
.,O
Braslia,LOCATION
.,O
29,NUMBER
(,O
3,NUMBER
),O
:,O
e2020233,O
.,O
2020,DATE
Betine,PERSON
Pinto,PERSON
Moehlecke,PERSON
Iser,PERSON
et,O
al,O
.,O
Flu,CAUSE_OF_DEATH
‐,O
like,O
syndrome,O
:,O
Individual,O
with,O
acute,O
respiratory,O
clinical,O
picture,O
.,O
characterized,O
by,O
feverish,O
sensation,O
or,O
fever,CAUSE_OF_DEATH
*,O
.,O
even,O
if,O
self,O
‐,O
re,O
‐,O
ported,O
.,O
together,O
with,O
coughing,O
OR,STATE_OR_PROVINCE
sore,O
throat,O
OR,O
runny,O
nose,O
OR,O
breathing,O
difficulty,O
.,O
*,O
Fever,CAUSE_OF_DEATH
may,O
not,O
be,O
present,DATE
in,O
suspected,O
COVID,O
‐,O
19,NUMBER
cases,O
.,O
Children,O
:,O
nasal,O
obstruction,O
can,O
also,O
be,O
consid,O
‐,O
ered,O
.,O
in,O
the,O
absence,O
of,O
other,O
specific,O
diagnosis,O
.,O
Elderly,O
:,O
fever,CAUSE_OF_DEATH
may,O
be,O
absent,O
.,O
Other,O
specific,O
criteria,O
indicating,O
worsening,O
con,O
‐,O
dition,O
should,O
be,O
considered,O
such,O
as,O
syncope,O
.,O
mental,O
confusion,O
.,O
excessive,O
sleepiness,O
.,O
irritability,O
and,O
loss,O
of,O
appetite,O
.,O
Case,O
Definitions,O
Severe,O
acute,O
respiratory,O
syndrome,O
:,O
Flu,CAUSE_OF_DEATH
‐,O
like,O
syndrome,O
presenting,O
:,O
dyspnea,O
/,O
breathing,O
discomfort,O
OR,O
persistent,O
tight,O
chest,O
OR,O
O2,O
saturation,O
below,O
95,PERCENT
%,PERCENT
in,O
ambient,O
air,O
OR,O
lips,O
or,O
face,O
with,O
bluish,O
color,O
.,O
Children,O
:,O
in,O
addition,O
to,O
the,O
preceding,O
items,O
.,O
observe,O
beating,O
of,O
wings,O
of,O
the,O
nose,O
.,O
cyanosis,O
.,O
intercostal,O
mus,O
‐,O
cle,O
straining,O
.,O
dehydration,O
and,O
loss,O
of,O
appetite,O
.,O
Situation,O
1,NUMBER
:,O
Fever,CAUSE_OF_DEATH
AND,O
at,O
least,O
one,NUMBER
respiratory,O
sign,O
or,O
symptom,O
(,O
coughing,O
.,O
breathing,O
difficulty,O
.,O
beating,O
of,O
wings,O
of,O
the,O
nose,O
.,O
among,O
others,O
),O
+,O
History,O
of,O
traveling,O
to,O
an,O
area,O
with,O
local,O
transmission,O
in,O
the,O
14,DURATION
days,DURATION
prior,O
to,O
onset,O
of,O
signs,O
or,O
symptoms,O
.,O
Traveler,O
:,O
Person,O
who,O
presents,O
fever,CAUSE_OF_DEATH
AND,O
at,O
least,O
one,NUMBER
respiratory,O
sign,O
or,O
symptom,O
+,O
History,O
of,O
traveling,O
to,O
a,O
country,O
with,O
sustained,O
transmission,O
OR,STATE_OR_PROVINCE
area,O
with,O
local,O
transmission,O
in,O
the,DURATION
last,DATE
14,DATE
days,DATE
.,O
Situation,O
2,NUMBER
:,O
Fever,CAUSE_OF_DEATH
AND,O
at,O
least,O
one,NUMBER
respiratory,O
sign,O
or,O
symptom,O
+,O
history,O
of,O
close,O
contact,O
with,O
suspected,O
case,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
in,O
the,DURATION
14,DURATION
days,DURATION
prior,O
to,O
onset,O
of,O
signs,O
or,O
symptoms,O
.,O
Situation,O
3,NUMBER
:,O
fever,CAUSE_OF_DEATH
OR,O
at,O
least,O
one,NUMBER
respiratory,O
sign,O
or,O
symptom,O
+,O
close,O
contact,O
with,O
labo,O
‐,O
ratory,O
‐,O
confirmed,O
case,O
.,O
in,O
the,DURATION
14,DURATION
days,DURATION
prior,O
to,O
onset,O
of,O
signs,O
or,O
symptoms,O
.,O
Close,O
contact,O
:,O
Person,O
who,O
presents,O
fever,CAUSE_OF_DEATH
OR,O
at,O
least,O
one,NUMBER
respiratory,O
sign,O
or,O
symptom,O
+,O
history,O
of,O
contact,O
with,O
sus,O
‐,O
pected,O
or,O
confirmed,O
case,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
in,O
the,DURATION
last,DATE
14,DATE
days,DATE
.,O
Household,O
contact,O
:,O
person,O
who,O
presents,O
fever,CAUSE_OF_DEATH
OR,O
at,O
least,O
one,NUMBER
res,O
‐,O
piratory,O
sign,O
or,O
symptom,O
#,O
+,O
household,O
contact,O
with,O
confirmed,O
case,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
the,DURATION
last,DATE
14,DATE
days,DATE
.,O
#,O
observe,O
presence,O
of,O
oth,O
‐,O
er,O
signs,O
and,O
symptoms,O
such,O
as,O
:,O
fatigue,O
.,O
myalgia,O
/,O
arthralgia,O
.,O
headache,O
.,O
shivering,O
.,O
red,O
patches,O
on,O
the,O
body,O
.,O
swollen,O
lymph,O
glands,O
.,O
diarrhea,O
.,O
nausea,O
.,O
vomiting,O
.,O
dehydration,O
and,O
loss,O
of,O
ap,O
‐,O
petite,O
.,O
Legend,O
:,O
COVID,O
‐,O
19,NUMBER
.,O
diseases,CAUSE_OF_DEATH
caused,O
by,O
Sars,O
‐,O
CoV,O
‐,O
2,NUMBER
;,O
EB,O
.,O
Brazilian,ORGANIZATION
Health,ORGANIZATION
Ministry,ORGANIZATION
Epidemiological,ORGANIZATION
Bulletin,ORGANIZATION
.,O
fever,CAUSE_OF_DEATH
.,O
tiredness,O
.,O
coughing,O
.,O
mild,O
dyspnea,O
.,O
anorexia,CAUSE_OF_DEATH
.,O
sore,O
throat,O
.,O
aching,O
body,O
.,O
headache,O
or,O
blocked,O
nose,O
.,O
some,O
may,O
also,O
have,O
diarrhea,O
.,O
nau,O
‐,O
sea,O
and,O
vomiting,O
.,O
Signs,O
and,O
symptoms,O
in,O
elderly,O
and,O
immunocompro,O
‐,O
mised,O
people,O
may,O
be,O
atypical,O
and,O
worsen,O
rapidly,O
.,O
which,O
can,O
cause,O
death,O
.,O
especially,O
in,O
the,O
case,O
of,O
the,O
elderly,O
and,O
people,O
with,O
pre,O
‐,O
existing,O
comorbidities,O
.,O
The,O
case,O
definitions,O
adopted,O
by,O
the,O
Brazilian,ORGANIZATION
Health,ORGANIZATION
Ministry,ORGANIZATION
were,O
established,O
in,O
February10,O
and,O
March,DATE
were,O
initially,O
based,O
on,O
the,O
occurrence,O
of,O
fever,CAUSE_OF_DEATH
and,O
at,O
least,O
one,NUMBER
respiratory,O
sign,O
or,O
symptom,O
.,O
with,O
a,O
history,O
of,O
the,O
per,O
‐,O
son,O
having,O
traveled,O
to,O
places,O
with,O
local,O
transmission,O
or,O
contact,O
with,O
a,O
confirmed,O
case,O
.11,NUMBER
However,O
.,O
fever,CAUSE_OF_DEATH
is,O
not,O
necessarily,O
present,DATE
in,O
all,O
affected,O
individuals,O
.7,NUMBER
considering,O
that,O
elderly,O
people,O
or,O
even,O
people,O
with,O
no,O
comorbidities,O
have,O
not,O
presented,O
this,O
specific,O
sign,O
.,O
Moreover,O
.,O
the,O
criterion,O
for,O
defining,O
fever,CAUSE_OF_DEATH
is,O
not,O
standardized,O
.,O
whereby,O
it,O
can,O
be,O
measured,O
as,O
temperature,O
37.5,NUMBER
C,O
.12,O
temperature,O
37.8,NUMBER
C,O
.7,O
recorded,O
on,O
medical,O
records,O
for,O
hos,O
‐,O
pitalized,O
cases13,O
or,O
even,O
reported,O
by,O
the,O
individual,O
without,O
con,O
‐,O
firmation,O
by,O
measuring,O
their,O
temperature,O
.7,NUMBER
Be,O
that,O
as,O
it,O
may,O
.,O
the,O
most,O
common,O
signs,O
and,O
symptoms,O
are,O
considered,O
to,O
be,O
fever,CAUSE_OF_DEATH
(,O
tem,O
‐,O
perature,O
37.8,NUMBER
C,O
),O
.,O
coughing,O
.,O
dyspnea,O
(,O
breathing,O
difficulty,O
),O
.,O
myal,O
‐,O
gia,O
and,O
fatigue,O
.11,NUMBER
A,O
study,O
of,O
41,NUMBER
confirmed,O
cases,O
in,O
China,COUNTRY
identi,O
‐,O
fied,O
that,O
98,PERCENT
%,PERCENT
of,O
them,O
had,O
fever,CAUSE_OF_DEATH
.,O
followed,O
by,O
coughing,O
(,O
76,PERCENT
%,PERCENT
),O
.,O
dys,O
‐,O
pnea,O
(,O
55,PERCENT
%,PERCENT
),O
and,O
myalgia,O
/,O
fatigue,O
(,O
44,PERCENT
%,PERCENT
),O
.14,NUMBER
Wang,O
et,O
al.,O
15,NUMBER
described,O
69,NUMBER
cases,O
in,O
China,COUNTRY
and,O
identified,O
that,O
some,O
15,PERCENT
%,PERCENT
of,O
individuals,O
an,O
‐,O
alyzed,O
had,O
fever,CAUSE_OF_DEATH
.,O
coughing,O
and,O
dyspnea,O
.,O
A,O
case,O
report,O
in,O
Seattle,CITY
.,O
United,COUNTRY
States,COUNTRY
.13,O
showed,O
that,O
50,PERCENT
%,PERCENT
of,O
cases,O
did,O
not,O
have,O
fever,CAUSE_OF_DEATH
and,O
that,O
coughing,O
and,O
dyspnea,O
were,O
the,O
most,O
reported,O
symptoms,O
.,O
ac,O
‐,O
counting,O
for,O
88,PERCENT
%,PERCENT
of,O
cases,O
.,O
In,O
findings,O
for,O
confirmed,O
COVID,O
‐,O
19,NUMBER
cases,O
.16,O
the,O
most,O
common,O
clinical,O
manifestations,O
were,O
fever,CAUSE_OF_DEATH
(,O
88.7,PERCENT
%,PERCENT
[,O
95,PERCENT
%,PERCENT
CI,O
84.5,NUMBER
;,O
92.9,PERCENT
%,PERCENT
],O
),O
.,O
coughing,O
(,O
57.6,PERCENT
%,PERCENT
[,O
95,PERCENT
%,PERCENT
CI,O
40.8,NUMBER
;,O
74.4,PERCENT
%,PERCENT
],O
),O
and,O
dyspnea,O
(,O
45.6,PERCENT
%,PERCENT
[,O
95,PERCENT
%,PERCENT
CI,O
10.9,NUMBER
;,O
80.4,PERCENT
%,PERCENT
],O
),O
.,O
although,O
they,O
may,O
not,O
be,O
present,DATE
.,O
Prevalence,O
of,O
fever,CAUSE_OF_DEATH
was,O
greater,O
in,O
adults,O
than,O
in,O
chil,O
‐,O
dren,O
.16,NUMBER
Epidemiol,O
.,O
Serv,O
.,O
Saude,PERSON
.,O
Braslia,LOCATION
.,O
29,NUMBER
(,O
3,NUMBER
),O
:,O
e2020233,O
.,O
2020,DATE
Suspected,O
COVID,O
‐,O
19,NUMBER
case,O
definition,O
There,O
are,O
also,O
reports,O
of,O
less,O
common,O
symptoms,O
that,O
are,O
hard,O
to,O
measure,O
objectively,O
.,O
such,O
as,O
anosmia,O
(,O
loss,O
of,O
sense,O
of,O
smell,O
),O
.,O
hyposmia,O
(,O
reduction,O
in,O
sense,O
of,O
smell,O
),O
and,O
ageusia,O
(,O
loss,O
of,O
sense,O
of,O
taste,O
),O
.,O
Specialist,TITLE
organiza,O
‐,O
tions,O
propose,O
that,O
anosmia,O
.,O
hyposmia,O
and,O
ageusia,O
should,O
be,O
in,O
‐,O
cluded,O
as,O
part,O
of,O
screening,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
principally,O
in,O
the,O
absence,O
of,O
other,O
respiratory,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
.,O
such,O
as,O
allergic,O
rhinitis,O
and,O
acute,O
or,O
chronic,O
rhinosinusitis,O
.17,NUMBER
There,O
is,O
evidence,O
of,O
a,O
significant,O
number,O
of,O
people,O
who,O
developed,O
these,O
symptoms,O
and,O
later,O
had,O
positive,O
COVID,O
‐,O
19,NUMBER
test,O
results,O
.18,NUMBER
‐,O
20,NUMBER
A,O
study,O
with,O
hospitalized,O
individuals,O
who,O
tested,O
positive,O
for,O
COVID,O
‐,O
19,NUMBER
in,O
Italy19,O
found,O
that,O
33.9,PERCENT
%,PERCENT
of,O
them,O
had,O
either,O
changes,O
to,O
sense,O
of,O
smell,O
or,O
taste,O
while,O
18.6,PERCENT
%,PERCENT
had,O
changes,O
to,O
both,O
.,O
Loss,O
of,O
sense,O
of,O
taste,O
occurred,O
in,O
91,PERCENT
%,PERCENT
before,O
they,O
were,O
hospitalized,O
.,O
These,O
symp,O
‐,O
toms,O
were,O
more,O
frequently,O
reported,O
by,O
women,O
(,O
52.6,PERCENT
%,PERCENT
versus,O
25,PERCENT
%,PERCENT
),O
and,O
by,O
less,O
elderly,O
people,O
(,O
median,O
of,O
56,DURATION
years,DURATION
.,O
IQR,O
47,NUMBER
‐,O
60,DURATION
years,DURATION
versus,O
66,DURATION
years,DURATION
.,O
IQR,O
52,NUMBER
‐,O
77,NUMBER
),O
.,O
In,O
Germany,COUNTRY
.,O
anosmia,O
was,O
found,O
in,O
more,O
than,O
two,NUMBER
thirds,O
of,O
individuals,O
studied,O
.,O
while,O
Italian,NATIONALITY
and,O
Swiss,NATIONALITY
doctors,O
are,O
reporting,O
similar,O
symptoms,O
.,O
with,O
many,O
also,O
hav,O
‐,O
ing,O
ageusia,O
.,O
In,O
South,COUNTRY
Korea,COUNTRY
.,O
anosmia,O
was,O
the,O
main,O
symptom,O
in,O
30,PERCENT
%,PERCENT
of,O
respondents,O
with,O
COVID,O
‐,O
19.18,NUMBER
In,O
a,O
cross,O
‐,O
sectional,O
study,O
with,O
204,NUMBER
laboratoryconfirmed,O
cases,O
in,O
China,COUNTRY
.21,NUMBER
gastrointestinal,O
symp,O
‐,O
toms,O
were,O
reported,O
by,O
50.5,PERCENT
%,PERCENT
at,O
the,O
time,DATE
they,O
were,O
admitted,O
to,O
hospital,O
.,O
in,O
addition,O
to,O
fever,CAUSE_OF_DEATH
and,O
respiratory,O
symptoms,O
.,O
Their,O
symptoms,O
included,O
ageusia,O
.,O
reported,O
by,O
78.6,PERCENT
%,PERCENT
of,O
cases,O
.,O
diarrhea,O
in,O
34,PERCENT
%,PERCENT
of,O
cases,O
.,O
as,O
well,O
as,O
vomiting,O
(,O
3.9,PERCENT
%,PERCENT
),O
and,O
abdominal,O
pain,O
(,O
1.9,PERCENT
%,PERCENT
),O
.,O
In,O
a,O
retrospective,O
study,O
conducted,O
in,O
the,O
Chinese,NATIONALITY
Prov,O
‐,O
ince,O
of,O
Zhejiang,STATE_OR_PROVINCE
.22,O
with,O
651,NUMBER
people,O
hospitalized,O
with,O
diagnosis,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
11.4,PERCENT
%,PERCENT
had,O
gastrointestinal,O
symptoms,O
when,O
they,O
were,O
admitted,O
to,O
hospital,O
.,O
The,O
most,O
prevalent,O
digestive,O
symptoms,O
were,O
diarrhea,O
(,O
71.62,PERCENT
%,PERCENT
),O
.,O
vomiting,O
(,O
14.86,PERCENT
%,PERCENT
),O
and,O
nausea,O
(,O
13.51,PERCENT
%,PERCENT
),O
.,O
Diag,O
‐,O
nosis,O
criteria,O
In,O
the,O
document,O
entitled,O
Guidelines,O
for,O
COVID,O
‐,O
19,NUMBER
Diagnosis,O
and,O
Treatment,O
.,O
given,O
the,O
inespecificity,O
and,O
heterogene,O
‐,O
ity,O
of,O
clinical,O
presentation,O
.,O
the,O
Ministry,ORGANIZATION
of,ORGANIZATION
Health,ORGANIZATION
considers,O
a,O
confirmed,O
case,O
to,O
be,O
a,O
case,O
with,O
conclusive,O
laboratory,O
confirma,O
‐,O
tion,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
regardless,O
of,O
signs,O
or,O
symptoms,O
.11,NUMBER
However,O
.,O
in,O
the,O
absence,O
of,O
confirmatory,O
diagnostic,O
tests,O
for,O
all,O
suspect,O
cases,O
.,O
health,O
services,O
have,O
had,O
to,O
adopt,O
a,O
very,O
sensitive,O
suspect,O
case,O
definition,O
.,O
especially,O
for,O
cases,O
with,O
mild,O
symptoms,O
.,O
consid,O
‐,O
ering,O
the,O
symptoms,O
reported,O
by,O
individuals,O
.,O
in,O
view,O
of,O
the,O
recom,O
‐,O
mendation,O
for,O
people,O
not,O
to,O
go,O
to,O
hospitals,O
or,O
health,O
centers,O
for,O
clinical,O
evaluation,O
.,O
in,O
the,O
absence,O
of,O
breathing,O
discomfort,O
as,O
a,O
sign,O
of,O
the,O
disease,CAUSE_OF_DEATH
becoming,O
worse,O
.8,NUMBER
As,O
such,O
.,O
using,O
the,O
clini,O
‐,O
cal,O
/,O
epidemiological,O
criterion,O
.,O
a,O
suspect,O
FS,O
or,O
SARS,O
case,O
is,O
con,O
‐,O
sidered,O
to,O
be,O
when,O
there,O
is,O
a,O
history,O
of,O
close,O
or,O
household,O
con,O
‐,O
tact,O
with,O
a,O
laboratory,O
confirmed,O
COVID,O
‐,O
19,NUMBER
case,O
during,O
the,O
seven,NUMBER
days,DURATION
prior,O
to,O
onset,O
of,O
symptoms,O
and,O
when,O
it,O
was,O
not,O
possible,O
to,O
perform,O
specific,O
laboratory,O
investigation,O
.,O
As,O
such,O
.,O
any,O
flu,CAUSE_OF_DEATH
‐,O
like,O
symptom,O
has,O
been,O
considered,O
to,O
indicate,O
a,O
suspect,O
case,O
.,O
above,O
all,O
with,O
the,O
aim,O
of,O
individual,O
isolation,O
so,O
as,O
to,O
avoid,O
virus,O
trans,O
‐,O
mission,O
.,O
Notwithstanding,O
.,O
it,O
is,O
known,O
that,O
the,O
majority,O
of,O
these,O
cases,O
considered,O
to,O
be,O
suspect,O
will,O
not,O
be,O
confirmed,O
.,O
unless,O
they,O
get,O
worse,O
and,O
need,O
to,O
be,O
hospitalized,O
.,O
or,O
voluntarily,O
have,O
rapid,O
tests,O
available,O
in,O
some,O
places,O
.,O
According,O
to,O
the,O
Ministry,O
of,O
Health,O
.,O
stratification,O
of,O
the,O
severity,O
of,O
suspect,O
FS,O
cases,O
should,O
take,O
place,O
during,O
a,O
medical,O
consultation,O
.,O
indicating,O
that,O
mild,O
cases,O
(,O
without,O
dyspnea,O
or,O
signs,O
and,O
symptoms,O
of,O
severity,O
),O
can,O
be,O
accompanied,O
completely,O
by,O
Primary,ORGANIZATION
Health,ORGANIZATION
Care,ORGANIZATION
and,O
Family,O
Health,O
Strategy,O
(,O
PHC,O
/,O
FHS,ORGANIZATION
),O
services,O
in,O
view,O
of,O
these,O
cases,O
being,O
less,O
se,O
‐,O
vere,O
.8,NUMBER
Those,O
who,O
have,O
FS,O
with,O
dyspnea,O
or,O
signs,O
and,O
symptoms,O
of,O
severity,O
.,O
or,O
together,O
with,O
comorbidities,O
that,O
contraindicate,O
home,O
isolation,O
.,O
need,O
stabilization,O
at,O
in,O
PHC,O
/,O
FHS,ORGANIZATION
services,O
and,O
referral,O
to,O
Reference,O
/,O
Urgency,O
/,O
Hospital,O
centers,O
for,O
24,NUMBER
‐,O
hour,DURATION
observation,O
or,O
interventions,O
involving,O
greater,O
technological,O
density,O
.,O
For,O
these,O
people,O
who,O
seek,O
care,O
at,O
a,O
health,O
service,O
facility,O
.,O
suspect,O
find,O
‐,O
ings,O
in,O
laboratory,O
tests,O
and,O
in,O
images,O
can,O
be,O
used,O
as,O
indications,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
assisting,O
with,O
suspect,O
case,O
diagnosis,O
.16.23,O
Molecular,O
tests,O
.,O
such,O
as,O
reverse,O
transcription,O
polymerase,O
chain,O
reaction,O
(,O
RT,MISC
‐,MISC
PCR,MISC
),O
.,O
which,O
identify,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
virus,O
RNA,MISC
.,O
should,O
be,O
used,O
between,O
the,O
3rd,ORDINAL
and,DATE
7th,DATE
day,DATE
of,O
symptoms,O
using,O
nasopharyngeal,O
secretion,O
samples,O
.,O
in,O
order,O
to,O
ensure,O
greater,O
precision,O
of,O
the,O
method,O
and,O
to,O
reduce,O
false,O
‐,O
negative,O
results,O
.24,NUMBER
Due,O
to,O
the,O
high,O
them,O
.,O
RT,O
‐,O
PCR,O
tests,O
are,O
used,O
for,O
hospitalized,O
symptomatic,O
individ,O
‐,O
uals,O
and,O
health,O
workers,O
.,O
Immunochromatographic,O
serological,O
tests,O
.,O
known,O
as,O
rapid,O
tests,O
.,O
have,O
become,O
an,O
option,O
for,O
people,O
with,O
light,O
to,O
moderate,O
symptoms,O
who,O
do,O
not,O
require,O
hospitalization,O
;,O
for,O
the,O
general,TITLE
population,O
.,O
when,O
screening,O
asymptomatic,O
cases,O
;,O
6,NUMBER
and,O
Epi,PERSON
‐,PERSON
demiol,O
.,O
Serv,O
.,O
Saude,PERSON
.,O
Braslia,LOCATION
.,O
29,NUMBER
(,O
3,NUMBER
),O
:,O
e2020233,O
.,O
2020,DATE
Betine,PERSON
Pinto,PERSON
Moehlecke,PERSON
Iser,PERSON
et,O
al,O
.,O
for,O
observing,O
immunity,O
/,O
recovery,O
of,O
con,O
‐,O
firmed,O
cases,O
.,O
In,O
this,O
case,O
.,O
rapid,O
tests,O
should,O
be,O
used,O
after,O
seven,DURATION
days,DURATION
following,O
onset,O
of,O
symptoms,O
.25,NUMBER
Development,O
of,O
a,O
sero,O
‐,O
logical,O
response,O
to,O
virus,O
infection,CAUSE_OF_DEATH
depends,O
on,O
the,O
host,TITLE
and,O
takes,O
time,O
.,O
In,O
the,O
case,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
initial,O
studies,O
suggest,O
that,O
the,O
majority,O
of,O
cases,O
seroconvert,O
between,O
7,NUMBER
and,O
11,DURATION
days,DURATION
following,O
ex,O
‐,O
posure,O
to,O
the,O
virus,O
.,O
As,O
a,O
result,O
of,O
this,O
natural,O
delay,O
.,O
an,O
anti,O
‐,O
body,O
test,O
may,O
not,O
be,O
useful,O
in,O
the,O
case,O
of,O
acute,O
disease,CAUSE_OF_DEATH
or,O
for,O
early,O
assessment,O
of,O
infection,CAUSE_OF_DEATH
.,O
Moreover,O
.,O
the,O
sensitivity,O
and,O
specificity,O
of,O
serological,O
tests,O
varies,O
according,O
to,O
the,O
manufac,O
‐,O
turer,O
.,O
In,O
general,TITLE
.,O
the,O
sensitivity,O
of,O
the,O
tests,O
approved,O
in,O
Brazil,COUNTRY
by,O
the,O
National,ORGANIZATION
Health,ORGANIZATION
Surveillance,ORGANIZATION
Agency,ORGANIZATION
(,O
ANVISA,O
),O
was,O
greater,O
than,O
85,PERCENT
%,PERCENT
.,O
and,O
specificity,O
was,O
greater,O
than,O
94,PERCENT
%,PERCENT
.4,NUMBER
It,O
is,O
important,O
to,O
highlight,O
that,O
diagnostic,O
tests,O
with,O
low,O
sensitivity,O
can,O
result,O
in,O
a,O
higher,O
proportion,O
of,O
false,O
‐,O
negative,O
results,O
.,O
and,O
this,O
could,O
interfere,O
in,O
the,O
social,O
isolation,O
measures,O
adopted,O
.,O
principally,O
for,O
asymptomatic,O
individuals,O
.,O
thus,O
having,O
a,O
direct,O
influence,O
on,O
virus,O
transmissibility,O
.,O
As,O
such,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
anti,O
‐,O
body,O
tests,O
can,O
facilitate,O
contact,O
screening,O
;,O
serological,O
surveil,O
‐,O
lance,O
at,O
the,O
local,O
.,O
regional,O
.,O
state,O
and,O
national,O
level,O
;,O
and,O
iden,O
‐,O
tification,O
of,O
those,O
who,O
have,O
already,O
been,O
exposed,O
and,O
may,O
possi,O
‐,O
bly,O
be,O
immune,O
.,O
considering,O
the,O
existence,O
of,O
protective,O
immunity,O
.,O
Characteristics,O
of,O
case,O
severity,O
Some,O
COVID,O
‐,O
19,NUMBER
cases,O
have,O
serious,O
complications,CAUSE_OF_DEATH
.,O
leading,O
to,O
the,O
need,O
for,O
care,O
in,O
intensive,O
therapy,O
units,O
(,O
ITU,O
),O
or,O
even,O
leading,O
to,O
death,O
.,O
According,O
to,O
the,O
Ministry,O
of,O
Health,O
.,O
besides,O
the,O
percentage,O
of,O
asymptomatic,O
cases,O
.,O
among,O
those,O
who,O
have,O
COVID,O
‐,O
19,NUMBER
.,O
around,O
80,PERCENT
%,PERCENT
are,O
mild,O
cases,O
.,O
14,PERCENT
%,PERCENT
are,O
se,O
‐,O
vere,O
cases,O
and,O
5,PERCENT
%,PERCENT
are,O
critical,O
cases,O
.7,NUMBER
As,O
for,O
more,O
complex,O
cases,O
.,O
they,O
either,O
progress,O
from,O
the,O
initial,O
symptoms,O
mentioned,O
above,O
.,O
or,O
they,O
already,O
manifest,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
through,O
SARS,O
.,O
by,O
having,O
dyspnea,O
or,O
clinical,O
signs,O
such,O
as,O
reduction,O
in,O
saturation,O
or,O
cyanosis,O
.8,NUMBER
In,O
addition,O
to,O
the,O
higher,O
mortality,O
rate,O
due,O
to,O
SARS,O
.,O
there,O
is,O
also,O
a,O
group,O
considered,O
to,O
be,O
at,O
risk,O
because,O
of,O
greater,O
lethality,O
.,O
Those,O
belonging,O
to,O
this,O
group,O
are,O
:,O
elderly,O
people,O
aged,O
60,NUMBER
and,O
over,O
.,O
high,O
‐,O
risk,O
pregnant,O
women,O
and,O
people,O
with,O
a,O
variety,O
of,O
comorbidities,O
.9,NUMBER
As,O
such,O
.,O
individuals,O
of,O
all,O
ages,O
who,O
have,O
chronic,O
diseases,CAUSE_OF_DEATH
related,O
to,O
the,O
lungs,O
.,O
asthma,CAUSE_OF_DEATH
.,O
those,O
who,O
currently,DATE
have,O
tuberculosis,CAUSE_OF_DEATH
or,O
sequelae,O
of,O
previous,O
tuberculosis,CAUSE_OF_DEATH
.,O
diabetes,CAUSE_OF_DEATH
.,O
hypertension,CAUSE_OF_DEATH
.,O
severe,O
obesity,O
.,O
chronic,O
kidney,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
.,O
liver,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
.,O
immunodeficiency,O
and,O
heart,O
problems,O
also,O
belong,O
to,O
the,O
risk,O
group,O
.,O
Recent,O
studies12,O
.26,O
‐,O
28,NUMBER
report,O
diabetes,CAUSE_OF_DEATH
mellitus,CAUSE_OF_DEATH
.,O
systemic,O
arterial,O
hypertension,CAUSE_OF_DEATH
.,O
cerebrovascular,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
and,O
age,O
as,O
more,O
decisive,O
risk,O
factors,O
in,O
relation,O
to,O
hospitalization,O
in,O
ITUs,O
and,O
death,O
.,O
A,O
retrospective,O
study,O
that,O
assessed,O
neurological,O
aspects,O
of,O
confirmed,O
COVID,O
‐,O
19,NUMBER
cases29,O
indicated,O
that,O
41.1,PERCENT
%,PERCENT
were,O
considered,O
severe,O
.,O
Compared,O
to,O
the,O
milder,O
cases,O
.,O
the,O
severe,O
cases,O
were,O
older,O
individuals,O
(,O
58.7,NUMBER
15.0,DURATION
years,DURATION
versus,O
48.9,NUMBER
14.7,NUMBER
years,DURATION
),O
.,O
had,O
more,O
comorbidities,O
(,O
42,NUMBER
[,O
47.7,PERCENT
%,PERCENT
],O
versus,O
41,NUMBER
[,O
32.5,PERCENT
%,PERCENT
],O
),O
.,O
especially,O
hypertension,CAUSE_OF_DEATH
(,O
32,NUMBER
[,O
36.4,PERCENT
%,PERCENT
],O
versus,O
19,NUMBER
[,O
15.1,PERCENT
%,PERCENT
],O
),O
.,O
and,O
had,O
fewer,O
symptoms,O
considered,O
to,O
be,O
typical,O
.,O
such,O
as,O
fever,CAUSE_OF_DEATH
(,O
40,NUMBER
[,O
45.5,PERCENT
%,PERCENT
],O
versus,O
92,NUMBER
[,O
73,PERCENT
%,PERCENT
],O
),O
and,O
coughing,O
(,O
30,NUMBER
[,O
34.1,PERCENT
%,PERCENT
],O
versus,O
77,NUMBER
[,O
61.1,PERCENT
%,PERCENT
],O
),O
.,O
Another,O
study,O
that,O
described,O
the,O
characteristics,O
of,O
cases,O
that,O
died,O
compared,O
to,O
cases,O
that,O
recovered30,O
found,O
at,O
least,O
one,NUMBER
chronic,O
disease,CAUSE_OF_DEATH
with,O
greater,O
frequency,O
among,O
cases,O
that,O
died,O
(,O
63,PERCENT
%,PERCENT
of,O
those,O
who,O
died,O
and,O
39,PERCENT
%,PERCENT
of,O
those,O
who,O
recovered,O
),O
.,O
whereby,O
the,O
main,O
diseases,CAUSE_OF_DEATH
were,O
:,O
systemic,O
arterial,O
hypertension,CAUSE_OF_DEATH
(,O
48,PERCENT
%,PERCENT
),O
.,O
cardiovascular,CAUSE_OF_DEATH
diseases,CAUSE_OF_DEATH
(,O
14,PERCENT
%,PERCENT
),O
and,O
cerebrovascular,O
diseases,CAUSE_OF_DEATH
(,O
4,PERCENT
%,PERCENT
),O
.,O
versus,O
24,PERCENT
%,PERCENT
.,O
4,PERCENT
%,PERCENT
and,O
0,PERCENT
%,PERCENT
.,O
respectively,O
.,O
in,O
recovered,O
cases,O
.,O
The,O
fol,O
‐,O
lowing,O
were,O
also,O
found,O
to,O
be,O
more,O
frequent,O
among,O
those,O
who,O
died,O
:,O
dyspnea,O
(,O
62,PERCENT
%,PERCENT
versus,O
31,PERCENT
%,PERCENT
),O
.,O
tight,O
chest,O
(,O
49,PERCENT
%,PERCENT
versus,O
30,PERCENT
%,PERCENT
),O
and,O
loss,O
of,O
consciousness,O
(,O
22,PERCENT
%,PERCENT
versus,O
1,PERCENT
%,PERCENT
),O
;,O
lymphopenia,O
(,O
39,PERCENT
%,PERCENT
),O
and,O
leukocy,O
‐,O
tosis,O
(,O
50,PERCENT
%,PERCENT
),O
(,O
versus,O
5,PERCENT
%,PERCENT
and,O
4,PERCENT
%,PERCENT
of,O
those,O
who,O
recovered,O
.,O
respective,O
‐,O
ly,O
),O
.,O
saturation,O
93,PERCENT
%,PERCENT
(,O
64,PERCENT
%,PERCENT
versus,O
12,PERCENT
%,PERCENT
),O
.,O
tachycardia,O
(,O
50,PERCENT
%,PERCENT
versus,O
30,PERCENT
%,PERCENT
),O
and,O
tachypnea,O
(,O
27,PERCENT
%,PERCENT
versus,O
3,PERCENT
%,PERCENT
),O
.,O
as,O
well,O
as,O
complications,CAUSE_OF_DEATH
that,O
can,O
arise,O
from,O
the,O
length,O
of,O
time,O
spent,O
in,O
ITUs,O
and,O
the,O
need,O
for,O
invasive,O
procedures,O
.,O
The,O
study,O
conducted,O
by,O
Wang,PERSON
et,O
al.,O
15,NUMBER
as,O
‐,O
sessed,O
69,NUMBER
people,O
with,O
COVID,O
‐,O
19,NUMBER
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
and,O
indicated,O
that,O
all,O
those,O
who,O
had,O
saturation,O
90,PERCENT
%,PERCENT
(,O
n,O
=,O
14.20,PERCENT
%,PERCENT
),O
died,O
.,O
and,O
that,O
those,O
who,O
died,O
were,O
older,O
(,O
median,O
of,O
70.5,DURATION
years,DURATION
versus,O
37,DURATION
years,DURATION
),O
.,O
with,O
comorbidities,O
such,O
as,O
systemic,O
arterial,O
hypertension,CAUSE_OF_DEATH
(,O
36,PERCENT
%,PERCENT
versus,O
7,PERCENT
%,PERCENT
),O
.,O
cardiovascular,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
(,O
36,PERCENT
%,PERCENT
versus,O
5,PERCENT
%,PERCENT
),O
and,O
diabetes,CAUSE_OF_DEATH
mellitus,O
(,O
43,PERCENT
%,PERCENT
versus,O
2,PERCENT
%,PERCENT
),O
.,O
and,O
had,O
a,O
substantial,O
increase,O
in,O
in,O
‐,O
flammatory,O
cytokines,O
.,O
Fever,CAUSE_OF_DEATH
was,O
evident,O
at,O
the,O
onset,O
of,O
symptoms,O
(,O
93,PERCENT
%,PERCENT
versus,O
85,PERCENT
%,PERCENT
),O
and,O
on,O
the,DATE
10th,DATE
day,DATE
of,O
illness,CAUSE_OF_DEATH
(,O
64,PERCENT
%,PERCENT
versus,O
38,PERCENT
%,PERCENT
),O
.,O
Dyspnea,PERSON
(,O
50,PERCENT
%,PERCENT
versus,O
24,PERCENT
%,PERCENT
),O
and,O
lymphopenia,O
(,O
79,PERCENT
%,PERCENT
versus,O
32,PERCENT
%,PERCENT
),O
were,O
also,O
more,O
frequent,O
in,O
this,O
group,O
.,O
A,O
study,O
that,O
investigated,O
the,O
characteristics,O
and,O
the,O
prognosis,O
factors,O
of,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
in,O
a,O
sample,O
Epidemiol,O
.,O
Serv,O
.,O
Saude,PERSON
.,O
Braslia,LOCATION
.,O
29,NUMBER
(,O
3,NUMBER
),O
:,O
e2020233,O
.,O
2020,DATE
Suspected,O
COVID,O
‐,O
19,NUMBER
case,O
definition,O
comprised,O
of,O
339,NUMBER
elderly,O
peo,O
‐,O
ple,O
(,O
60,DURATION
years,DURATION
old,DURATION
),O
with,O
positive,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
test,O
results,O
.30,NUMBER
found,O
that,O
the,O
number,O
of,O
critical,O
and,O
severe,O
cases,O
was,O
greater,O
in,O
the,O
group,O
analyzed,O
compared,O
to,O
cases,O
under,O
60,DURATION
years,DURATION
old,DURATION
.,O
The,O
study,O
indicated,O
that,O
23.6,PERCENT
%,PERCENT
were,O
classified,O
as,O
being,O
in,O
a,O
critical,O
state,O
.,O
while,O
a,O
further,O
46.9,PERCENT
%,PERCENT
were,O
in,O
a,O
severe,O
state,O
.30,NUMBER
The,O
Chi,O
‐,O
nese,O
Center,ORGANIZATION
for,ORGANIZATION
Disease,ORGANIZATION
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
carried,O
out,O
a,O
study,O
with,O
1.023,NUMBER
positive,O
COVID,O
‐,O
19,NUMBER
cases,O
.23,NUMBER
Among,O
those,O
who,O
be,O
‐,O
came,O
severely,O
ill,O
.,O
the,O
most,O
common,O
clinical,O
signs,O
were,O
dyspnea,O
.,O
respiratory,O
rate,O
greater,O
than,O
30,NUMBER
bpm,O
and,O
oxygen,O
saturation,O
under,O
93,PERCENT
%,PERCENT
.,O
Among,O
the,O
more,O
critical,O
cases,O
.,O
the,O
signs,O
most,O
found,O
were,O
respiratory,O
insufficiency,O
.,O
septic,O
shock,O
and,O
dysfunction,O
or,O
fail,O
‐,O
ure,O
of,O
multiple,O
organs,O
.,O
Lethality,O
was,O
2.3,PERCENT
%,PERCENT
in,O
that,O
sample,O
.,O
Howev,O
‐,O
er,O
.,O
if,O
only,O
the,O
lethality,O
of,O
the,O
critical,O
cases,O
were,O
assessed,O
.,O
the,O
proportion,O
would,O
be,O
much,O
higher,O
.,O
i.e.,O
49,PERCENT
%,PERCENT
.,O
the,O
most,O
common,O
signs,O
and,O
symptoms,O
by,O
sex,O
and,O
age,O
.,O
although,O
age,O
is,O
more,O
related,O
to,O
the,O
diseases,CAUSE_OF_DEATH
severity,O
criteria,O
.,O
It,O
is,O
important,O
to,O
consider,O
that,O
signs,O
and,O
symptoms,O
can,O
vary,O
between,O
the,O
stages,O
of,O
the,O
dis,O
‐,O
ease,O
.,O
oscillating,O
between,O
absence,O
of,O
signs,O
and,O
symptoms,O
and,O
sep,DATE
‐,O
tic,O
shock,O
.,O
when,O
the,O
clinical,O
picture,O
becomes,O
worse,O
.,O
It,O
should,O
also,O
be,O
noted,O
that,O
in,O
addition,O
to,O
the,O
diversity,O
of,O
clinical,O
mani,O
‐,O
festations,O
.,O
some,O
80,PERCENT
%,PERCENT
of,O
infected,O
people,O
can,O
remain,O
asymptomatic,O
.,O
It,O
is,O
therefore,O
suggested,O
that,O
suspect,O
cases,O
should,O
be,O
monitored,O
constantly,O
.,O
in,O
view,O
of,O
the,O
manifestations,O
of,O
diverse,O
symptoms,O
.,O
so,O
as,O
not,O
to,O
rule,O
out,O
cases,O
by,O
only,O
considering,O
clinical,O
presenta,O
‐,O
tion,O
which,O
.,O
in,O
many,O
cases,O
.,O
is,O
subjective,O
.,O
Given,O
the,O
imminence,O
of,O
Brazil,COUNTRY
becoming,O
the,O
worlds,O
new,O
epicenter,O
of,O
the,O
COVID,O
‐,O
19,NUMBER
pandem,O
‐,O
ic,O
.,O
it,O
is,O
suggested,O
that,O
health,O
services,O
opt,O
for,O
over,O
‐,O
reporting,O
.,O
considering,O
the,O
high,O
sensitivity,O
of,O
the,O
surveillance,O
system,O
.,O
so,O
that,O
whenever,O
signs,O
and,O
symptoms,O
appear,O
that,O
may,O
be,O
related,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
isolation,O
measures,O
can,O
be,O
indicated,O
for,O
cases,O
and,O
their,O
contacts,O
.,O
in,O
addition,O
to,O
constant,O
real,O
‐,O
time,O
moni,O
‐,O
toring,O
.,O
based,O
on,O
case,O
investigation,O
and,O
local,O
epidemiological,O
re,O
‐,O
ality,O
.,O
In,O
addition,O
.,O
health,O
services,O
can,O
establish,O
.,O
based,O
on,O
the,O
cases,O
they,O
care,O
for,O
.,O
a,O
set,O
of,O
signs,O
and,O
symptoms,O
that,O
best,O
de,O
‐,O
fines,O
their,O
cases,O
and,O
which,O
guides,O
screening,O
in,O
accordance,O
with,O
the,O
specific,O
situation,O
.,O
Use,O
of,O
telemedicine,O
is,O
a,O
fundamental,O
tool,O
in,O
providing,O
care,O
to,O
suspect,O
and,O
confirmed,O
cases,O
that,O
can,O
stay,O
at,O
home,O
.,O
so,O
as,O
to,O
accompany,O
the,O
progression,O
of,O
their,O
clinical,O
pre,O
‐,O
sentation,O
and,O
identify,O
early,O
any,O
worsening,O
of,O
the,O
case,O
.,O
so,O
that,O
appropriate,O
measures,O
can,O
be,O
taken,O
.,O
Whenever,O
possible,O
.,O
it,O
is,O
es,O
‐,O
sential,O
to,O
use,O
molecular,O
or,O
serological,O
diagnostic,O
tests,O
.,O
depend,O
‐,O
ing,O
on,O
the,DATE
day,DATE
the,O
symptoms,O
started,O
.,O
in,O
addition,O
to,O
laboratory,O
tests,O
and,O
image,O
examinations,O
.,O
to,O
confirm,O
diagnosis,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Final,O
considerations,O
against,O
it,O
using,O
the,O
best,O
available,O
evi,O
‐,O
dence,O
.,O
Due,O
to,O
its,O
multiple,O
presentations,O
in,O
all,O
age,O
ranges,O
.,O
the,O
concept,O
of,O
diagnosis,O
continues,O
to,O
be,O
very,O
broad,O
and,O
sensitive,O
.,O
so,O
that,O
it,O
is,O
not,O
possible,O
to,O
define,O
so,O
much,O
as,O
a,O
single,O
obligatory,O
sign,O
/,O
symptom,O
for,O
determining,O
presence,O
of,O
infection,CAUSE_OF_DEATH
.,O
Nevertheless,O
.,O
it,O
appears,O
to,O
be,O
consensus,O
that,O
people,O
with,O
existing,O
comorbidi,O
‐,O
ties,O
and,O
people,O
who,O
are,O
older,O
are,O
susceptible,O
to,O
being,O
more,O
in,O
‐,O
tensely,O
affected,O
and,O
having,O
worse,O
disease,CAUSE_OF_DEATH
progression,O
.,O
so,O
that,O
they,O
need,O
to,O
be,O
targeted,O
with,O
preventive,O
actions,O
.,O
Considering,O
the,O
high,O
percentage,O
of,O
asymptomatic,O
people,O
and,O
people,O
with,O
mild,O
symptoms,O
.,O
who,O
will,O
not,O
be,O
completely,O
captured,O
by,O
the,O
surveillance,O
system,O
.,O
by,O
means,O
of,O
investigation,O
and,O
laboratory,O
confirmation,O
.,O
health,O
services,O
need,O
to,O
take,O
great,O
care,O
with,O
regard,O
to,O
symptom,O
heterogeneity,O
and,O
clinical,O
presentation,O
of,O
the,O
disease,CAUSE_OF_DEATH
.,O
In,O
this,O
situation,O
.,O
nonpharmaceutical,O
prevention,O
measures,O
need,O
to,O
be,O
adopted,O
for,O
the,O
entire,O
population,O
.,O
including,O
wearing,O
facemasks,O
.,O
constant,O
sanitization,O
of,O
hands,O
and,O
environments,O
.,O
in,O
addition,O
to,O
social,O
distancing,O
.,O
It,O
also,O
continues,O
to,O
be,O
essential,O
to,O
increase,O
access,O
to,O
diagnostic,O
tests,O
.,O
in,O
order,O
to,O
have,O
knowledge,O
of,O
the,O
epidemiological,O
situation,O
in,O
each,O
place,O
and,O
achieve,O
better,O
guid,O
‐,O
ance,O
of,O
measures,O
to,O
control,O
virus,O
dissemination,O
.,O
Brazil,COUNTRY
contin,O
‐,O
ues,O
to,O
be,O
in,O
a,O
state,O
of,O
alert,O
.,O
with,O
the,O
aim,O
of,O
slowing,O
down,O
the,O
new,O
case,O
infection,CAUSE_OF_DEATH
curve,O
so,O
as,O
not,O
to,O
overburden,O
the,O
health,O
sys,O
‐,O
tem,O
.,O
Further,O
studies,O
need,O
to,O
be,O
conducted,O
so,O
that,O
the,O
case,O
defi,O
‐,O
nition,O
becomes,O
more,O
precise,O
in,O
relation,O
to,O
signs,O
and,O
symptoms,O
.,O
assisting,O
classification,O
of,O
the,O
population,O
and,O
guiding,O
the,O
gradu,O
‐,O
al,O
return,O
to,O
routine,O
activities,O
.,O
while,O
complying,O
with,O
indicated,O
protection,O
measures,O
.,O
with,O
the,O
aim,O
of,O
minimizing,O
the,O
consequences,O
of,O
the,O
pandemic,O
.,O
Iser,O
BPM,O
.,O
Schuelter,O
‐,O
Trevisol,O
F,O
and,O
Bobinski,PERSON
F,O
contributed,O
to,O
the,O
study,O
concept,O
and,O
design,O
.,O
Iser,O
BPM,O
coordinated,O
Epidemiol,O
.,O
Serv,O
.,O
Saude,PERSON
.,O
Braslia,LOCATION
.,O
29,NUMBER
(,O
3,NUMBER
),O
:,O
e2020233,O
.,O
2020,DATE
Betine,O
Pin,O
‐,O
to,O
Moehlecke,PERSON
Iser,PERSON
et,O
al,O
.,O
the,O
research,O
team,O
.,O
Sliva,PERSON
I,O
.,O
Raymundo,PERSON
VT,PERSON
and,O
Poleto,O
MB,STATE_OR_PROVINCE
BPM,O
.,O
Schuelter,O
‐,O
Trevisol,O
F,O
.,O
Bobinski,PERSON
F,O
.,O
Sliva,PERSON
I,O
.,O
Raymundo,PERSON
VT,PERSON
and,O
Poleto,O
MB,STATE_OR_PROVINCE
contributed,O
to,O
data,O
interpretation,O
.,O
drafting,O
including,O
the,O
guarantee,O
of,O
its,O
accuracy,O
and,O
integrity,O
.,O
1,NUMBER
.,O
Zhu,PERSON
N,PERSON
.,O
Zhang,PERSON
D,PERSON
.,O
Wang,PERSON
W,PERSON
.,O
Li,PERSON
X,PERSON
.,O
Yang,PERSON
B,O
.,O
Song,O
J,O
.,O
et,O
al,O
.,O
A,O
novel,O
coronavirus,O
from,O
patients,O
with,O
pneumonia,CAUSE_OF_DEATH
in,O
China,COUNTRY
.,O
2019,DATE
.,O
N,O
Engl,PERSON
J,PERSON
Med,MISC
[,MISC
Internet,MISC
],O
.,O
2020,DATE
Feb,DATE
[,O
cited,O
2,NUMBER
.,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
‐,O
WHO,O
.,O
Coronavirus,O
disease,CAUSE_OF_DEATH
(,O
COVID,O
‐,O
19,NUMBER
),O
pandemic,O
[,O
Internet,MISC
],O
.,O
Geneva,CITY
:,O
World,ORGANIZATION
Health,ORGANIZATION
Organization,ORGANIZATION
;,O
2019,DATE
[,O
cited,O
2020,DATE
Apr,DATE
26,DATE
],O
.,O
3,NUMBER
.,O
Croda,PERSON
J,PERSON
.,O
Oliveira,PERSON
WK,DURATION
.,O
Frutuoso,ORGANIZATION
RL,ORGANIZATION
.,O
Mandetta,ORGANIZATION
LH,ORGANIZATION
.,O
Baia,PERSON
‐,O
da,O
‐,O
Silva,LOCATION
DC,STATE_OR_PROVINCE
.,O
Brito,PERSON
‐,O
Sousa,PERSON
JD,PERSON
.,O
et,O
al,O
.,O
COVID,O
‐,O
19,NUMBER
in,O
Brazil,COUNTRY
:,O
advantages,O
of,O
a,O
socialized,O
unified,O
health,O
Bras,O
Med,O
Trop,O
[,O
Internet,MISC
],O
.,O
2020,DATE
Apr,DATE
[,O
cited,O
2020,DATE
4,NUMBER
.,O
Ministrio,PERSON
da,PERSON
Sade,PERSON
(,O
BR,O
),O
.,O
Secretaria,O
de,O
Cincia,O
.,O
Tecnologia,LOCATION
.,O
Inovao,PERSON
e,O
Insumos,ORGANIZATION
Estratgicos,ORGANIZATION
em,ORGANIZATION
Sade,ORGANIZATION
.,O
Acurcia,O
dos,O
testes,O
diagnsticos,O
registrados,O
para,O
a,O
COVID,O
‐,O
19,NUMBER
:,O
verso,O
1,NUMBER
[,O
Internet,MISC
],O
.,O
Braslia,O
:,O
Min,DURATION
‐,O
istrio,O
da,O
Sade,O
;,O
2020,DATE
[,O
citado,O
2020,DATE
jun,DATE
1,DATE
],O
.,O
19,NUMBER
p.,O
5,NUMBER
.,O
Zitek,PERSON
T.,O
The,O
appropriate,O
use,O
of,O
testing,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
West,O
J,O
Emerg,O
Med,O
[,O
In,O
‐,O
ternet,O
],O
.,O
2020,DATE
Apr,DATE
[,O
cited,O
2020,DATE
6,NUMBER
.,O
Tolia,PERSON
VM,PERSON
.,O
Chan,ORGANIZATION
TC,ORGANIZATION
.,O
Castillo,PERSON
EM,O
.,O
Preliminary,O
results,O
of,O
initial,O
testing,O
for,O
coronavirus,O
(,O
COVID,O
‐,O
19,NUMBER
),O
in,O
the,O
emergency,O
department,O
.,O
West,O
J,O
Emerg,O
Med,O
[,O
Internet,MISC
],O
.,O
2020,DATE
Mar,DATE
[,O
cited,O
2020,DATE
Jun,DATE
1,DATE
],O
;,O
21,NUMBER
(,O
3,NUMBER
),O
:,O
503,NUMBER
‐,O
6,NUMBER
.,O
Available,O
7,NUMBER
.,O
Ministrio,O
da,O
Sade,O
(,O
BR,O
),O
.,O
Secretaria,O
de,O
Vigilncia,O
em,O
Sade,O
.,O
Centro,O
de,O
Operaes,O
de,O
Emergncias,O
em,O
Sade,PERSON
Pblica,PERSON
.,O
Doena,O
pelo,O
coronavrus,O
2019,DATE
:,O
ampliao,O
da,O
vigilncia,O
.,O
medidas,O
no,O
farmacolgicas,O
e,O
descentralizao,O
do,O
diagnsti,O
‐,O
co,O
laboratorial,O
.,O
Bol,MISC
Epidemiol,MISC
[,MISC
Internet,MISC
],O
.,O
2020,DATE
mar,DATE
[,O
citado,O
2020,DATE
jun,DATE
1,DATE
],O
;,O
5,NUMBER
.,O
8,NUMBER
.,O
Ministrio,PERSON
da,PERSON
Sade,PERSON
(,O
BR,O
),O
.,O
Secretaria,O
de,O
Vigilncia,O
em,O
Sade,O
.,O
Guia,O
de,O
vigilncia,O
epidemiolgica,O
emergncia,O
de,O
sade,O
pblica,O
de,O
importncia,O
nacional,O
pela,O
doena,O
pelo,O
coronavrus,O
2019,DATE
[,O
Internet,MISC
],O
.,O
Braslia,O
:,O
Ministrio,ORGANIZATION
da,ORGANIZATION
Sade,ORGANIZATION
;,O
2020,DATE
[,O
citado,O
2020,DATE
jun,DATE
1,DATE
],O
.,O
34,NUMBER
p.,O
Disponvel,O
9,NUMBER
.,O
Ministrio,PERSON
da,PERSON
Sade,PERSON
.,O
Secretaria,O
de,O
Vigilncia,O
em,O
Sade,O
.,O
Centro,O
de,O
Operaes,O
de,O
Emergncias,O
em,O
Sade,O
Pblica,O
.,O
Especial,O
:,O
doena,O
pelo,O
coronavrus,O
2019,DATE
.,O
Bol,MISC
Epidemiol,MISC
[,MISC
Internet,MISC
],O
.,O
2020,DATE
abr,O
[,O
citado,O
10,NUMBER
.,O
Ministrio,PERSON
da,PERSON
Sade,PERSON
(,O
BR,O
),O
.,O
Secretaria,O
de,O
Vigilncia,O
em,O
Sade,O
.,O
Cen,O
‐,O
tro,O
de,O
Operaes,O
de,O
Emergncias,O
em,O
Sade,O
Pblica,O
.,O
Infeco,O
humana,O
pelo,O
novo,O
coronavrus,O
(,O
2019,DATE
‐,O
nCoV,O
),O
.,O
Bol,MISC
Epidemiol,MISC
[,MISC
Internet,MISC
],O
.,O
2020,DATE
jan,DATE
[,O
citado,O
2020,DATE
jun,DATE
1,DATE
],O
;,O
1,NUMBER
.,O
Disponvel,O
em,O
:,O
11,NUMBER
.,O
Ministrio,PERSON
da,PERSON
Sade,PERSON
(,O
BR,O
),O
.,O
Secretaria,O
de,O
Cincia,O
.,O
Tecnologia,LOCATION
.,O
Inovao,PERSON
e,O
Insumos,O
Estratgicos,O
em,O
Sade,O
.,O
Diretrizes,O
para,O
diagnstico,O
e,O
tratamento,O
da,O
COVID,O
‐,O
19,NUMBER
[,O
Inter,O
‐,O
net,O
],O
.,O
Braslia,O
:,O
Ministrio,ORGANIZATION
da,ORGANIZATION
Sade,ORGANIZATION
;,O
2020,DATE
[,O
citado,O
2020,DATE
jun,DATE
1,DATE
],O
.,O
87,NUMBER
p.,O
Disponvel,O
em,O
:,O
12,NUMBER
.,O
Guan,O
W,O
.,O
Ni,MISC
Z,O
.,O
Hu,O
Y,O
.,O
Liang,PERSON
W,PERSON
.,O
Ou,O
C,O
.,O
He,O
J,O
.,O
et,O
al,O
.,O
Clinical,O
characteristics,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
in,O
China,COUNTRY
.,O
N,O
Engl,O
J,O
Med,O
[,O
Internet,MISC
],O
.,O
2020,DATE
Apr,DATE
[,O
cited,O
2020,DATE
Jun,PERSON
Epidemiol,PERSON
.,O
Serv,O
.,O
Saude,PERSON
.,O
Braslia,LOCATION
.,O
29,NUMBER
(,O
3,NUMBER
),O
:,O
e2020233,O
.,O
2020,DATE
Suspected,O
COVID,O
‐,O
19,NUMBER
case,O
def,O
‐,O
inition,O
13,NUMBER
.,O
Bhatraju,ORGANIZATION
PK,ORGANIZATION
.,O
Ghassemieh,PERSON
BJ,PERSON
.,O
Nichols,PERSON
M,O
.,O
Kim,PERSON
R,PERSON
.,O
Jerome,PERSON
KR,O
.,O
Nalla,ORGANIZATION
AK,ORGANIZATION
.,O
et,O
al,O
.,O
Covid,O
‐,O
19,NUMBER
in,O
critically,O
Ill,STATE_OR_PROVINCE
patients,O
in,O
the,O
Seattle,CITY
Region,O
case,O
series,O
.,O
N,O
Engl,O
J,O
Med,O
[,O
Internet,MISC
],O
.,O
2020,DATE
Mar,DATE
[,O
cited,O
2020,DATE
14,DATE
.,O
Huang,PERSON
C,PERSON
.,O
Wang,O
Y,O
.,O
Li,PERSON
X,PERSON
.,O
Ren,PERSON
L,PERSON
.,O
Zhao,PERSON
J,PERSON
.,O
Hu,O
Y,O
.,O
et,O
al,O
.,O
Clinical,O
features,O
of,O
patients,O
infected,O
with,O
2019,DATE
novel,O
coro,O
‐,O
navirus,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
Lancet,O
[,O
Internet,MISC
],O
.,O
2020,DATE
Feb,DATE
[,O
cited,O
2020,DATE
Jun,DATE
1,DATE
],O
;,O
395,NUMBER
(,O
10223,NUMBER
),O
:,O
497,NUMBER
‐,O
506,NUMBER
.,O
Available,O
15,NUMBER
.,O
Wang,O
Z,O
.,O
Yang,PERSON
B,PERSON
.,O
Li,PERSON
Q,O
.,O
Wen,PERSON
L,PERSON
.,O
Zhang,PERSON
R.,PERSON
Clinical,PERSON
features,O
of,O
69,NUMBER
cases,O
with,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
Clin,O
Infect,O
Dis,O
[,O
Internet,MISC
],O
.,O
Foth,PERSON
‐,PERSON
coming,O
.,O
16,NUMBER
.,O
Rodriguez,PERSON
‐,O
Morales,PERSON
AJ,PERSON
.,O
Cardona,PERSON
‐,O
Ospina,O
JA,O
.,O
GutirrezO,O
‐,O
campo,O
E,O
.,O
Villamizar,PERSON
‐,O
Pea,O
R,O
.,O
Holguin,PERSON
‐,O
Rivera,O
Y,O
.,O
Escalera,O
‐,O
Antezana,PERSON
JP,O
.,O
et,O
al,O
.,O
Clinical,O
.,O
laboratory,O
and,O
and,O
meta,O
‐,O
analysis,O
.,O
Travel,O
Med,O
Infect,O
Dis,O
[,O
Internet,MISC
],O
.,O
2020,DATE
Mar,DATE
‐,O
Abr,O
[,O
cited,O
2020,DATE
Jun,PERSON
1,NUMBER
],O
;,O
34:101623,NUMBER
.,O
Available,O
17,NUMBER
.,O
Sociedade,ORGANIZATION
Brasileira,ORGANIZATION
de,O
Cirurgia,O
de,O
Cabea,PERSON
e,O
Pescoo,O
‐,O
SBCCP,O
.,O
Anosmia,O
.,O
hiposmia,O
e,O
ageusia,O
‐,O
sintomas,O
na,O
infeco,O
por,O
COVID,O
‐,O
19,NUMBER
?,O
So,O
Paulo,O
:,O
Sociedade,ORGANIZATION
Brasileira,ORGANIZATION
de,ORGANIZATION
Cirurgia,ORGANIZATION
de,PERSON
Cabea,PERSON
e,O
Pescoo,LOCATION
;,O
2020,DATE
18,DATE
.,O
Gautier,PERSON
JF,PERSON
.,O
Ravussin,PERSON
Y,PERSON
.,O
A,O
new,O
symptom,O
of,O
COVID,O
‐,O
19,NUMBER
:,O
loss,O
of,O
taste,O
and,O
smell,O
.,O
Obesity,MISC
[,MISC
Internet,MISC
],O
.,O
2020,DATE
Apr,DATE
19,DATE
.,O
Giacomelli,PERSON
A,O
.,O
Pezzati,PERSON
L,PERSON
.,O
Conti,PERSON
F,O
.,O
Bernacchia,O
D,O
.,O
Siano,PERSON
M,O
.,O
Oreni,MISC
L,MISC
.,O
et,O
al,O
.,O
Self,O
‐,O
reported,O
olfactory,O
and,O
taste,O
disorders,O
in,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
patients,O
:,O
a,O
cross,O
‐,O
sectional,O
study,O
.,O
Clin,PERSON
Infect,PERSON
Dis,PERSON
[,O
Internet,MISC
],O
.,O
Fothcoming,O
2020,DATE
20,DATE
.,O
Vaira,PERSON
LA,PERSON
.,O
Salzano,PERSON
G,PERSON
.,O
Deiana,PERSON
G,PERSON
.,O
De,PERSON
Riu,PERSON
G.,PERSON
Anosmia,PERSON
and,O
ageusia,O
:,O
common,O
findings,O
in,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
Laryngoscope,MISC
[,MISC
Internet,MISC
],O
.,O
Forthcoming,O
2020,DATE
Apr,DATE
[,O
cited,O
21,NUMBER
.,O
Pan,O
L,O
.,O
Mu,O
M,O
.,O
Yang,PERSON
P,O
.,O
Sun,O
Y,O
.,O
Yan,PERSON
J,PERSON
.,O
Li,PERSON
P,PERSON
.,O
et,O
al,O
.,O
Clinical,O
characteristics,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
with,O
digestive,O
symptoms,O
in,O
Hubei,STATE_OR_PROVINCE
.,O
China,COUNTRY
:,O
a,O
descriptive,O
.,O
crosssectional,O
.,O
multicenter,O
study,O
.,O
Am,O
J,O
Gastroen,O
‐,O
terol,O
22,NUMBER
.,O
Jin,PERSON
X,PERSON
.,O
Lian,O
J,O
‐,O
S,O
.,O
Hu,O
J,O
‐,O
H,O
.,O
Gao,PERSON
J,PERSON
.,O
Zheng,PERSON
L,PERSON
.,O
Zhang,O
Y,O
‐,O
M,O
.,O
et,O
al,O
.,O
Epidemiological,O
.,O
clinical,O
and,O
virological,O
characteristics,O
of,O
74,NUMBER
cases,O
of,O
coronavirus,O
‐,O
infected,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
with,O
gastrointestinal,O
symptoms,O
.,O
Gut,O
[,O
Internet,MISC
],O
.,O
2020,DATE
Jun,DATE
[,O
cited,O
2020,DATE
23,NUMBER
.,O
Wu,O
Z,O
.,O
McGoogan,PERSON
JM,PERSON
.,O
Characteristics,O
of,O
and,O
important,O
lessons,O
from,O
the,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
outbreak,O
in,O
china,COUNTRY
:,O
summary,O
of,O
a,O
report,O
of,O
72,NUMBER
314,NUMBER
cases,O
from,O
the,O
chinese,NATIONALITY
center,O
for,O
disease,CAUSE_OF_DEATH
control,O
and,O
prevention,O
.,O
JAMA,O
[,O
Internet,MISC
],O
.,O
2020,DATE
Fev,O
[,O
cited,O
2020,DATE
Jun,DATE
1,DATE
],O
;,O
323,NUMBER
(,O
13,NUMBER
),O
:,O
1239,DATE
‐,O
42,NUMBER
.,O
Available,O
from,O
:,O
24,NUMBER
.,O
Woelfel,PERSON
R,PERSON
.,O
Cor,PERSON
‐,PERSON
man,O
VM,O
.,O
Guggemos,PERSON
W,PERSON
.,O
Seilmaier,O
M,O
.,O
Zange,PERSON
S,PERSON
.,O
Mueller,PERSON
MA,PERSON
.,O
et,O
al,O
.,O
Clinical,O
presentation,O
and,O
virological,O
assessment,O
of,O
hospitalized,O
cases,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
in,O
a,O
travel,O
‐,O
associated,O
trans,O
‐,O
mission,O
cluster,O
.,O
medRxiv,O
[,O
Internet,MISC
],O
.,O
Forthcoming,O
2020,DATE
Mar,DATE
[,O
cited,O
2020,DATE
Jun,DATE
1,DATE
],O
.,O
Available,O
25,NUMBER
.,O
Hadaya,PERSON
J,PERSON
.,O
Schumm,PERSON
M,O
.,O
Livingston,PERSON
EH,O
.,O
Testing,O
individuals,O
for,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
JAMA,PERSON
[,O
Internet,MISC
],O
.2020,NUMBER
Apr,DATE
[,O
cited,O
2020,DATE
26,DATE
.,O
Yang,PERSON
J,PERSON
.,O
Zheng,PERSON
Y,PERSON
.,O
Gou,PERSON
X,PERSON
.,O
Pu,PERSON
K,PERSON
.,O
Chen,O
Z,O
.,O
Guo,PERSON
Q,O
.,O
et,O
al,O
.,O
Prevalence,O
of,O
comorbidities,O
in,O
the,O
novel,O
Wuhan,CITY
and,O
meta,O
‐,O
analysis,O
.,O
Int,O
J,O
Infect,O
Dis,O
[,O
Internet,MISC
],O
.,O
2020,DATE
May,DATE
[,O
cited,O
2020,DATE
Jun,DATE
1,DATE
],O
;,O
94:91,NUMBER
‐,O
5,NUMBER
.,O
Available,O
from,O
:,O
27,NUMBER
.,O
Yang,O
X,O
.,O
Yu,O
Y,O
.,O
Xu,PERSON
J,O
.,O
Shu,PERSON
H,PERSON
.,O
Xia,PERSON
J,PERSON
.,O
Liu,PERSON
H,O
.,O
et,O
al,O
.,O
Clinical,O
course,O
and,O
outcomes,O
of,O
critically,O
ill,O
patients,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
.,O
Chi,O
‐,O
na,O
:,O
a,O
singlecentered,O
.,O
retrospective,O
.,O
observational,O
study,O
.,O
Lancet,O
Respir,O
Med,O
[,O
Internet,MISC
],O
.,O
2020,DATE
May,DATE
[,O
cited,O
2020,DATE
Epidemiol,O
.,O
Serv,O
.,O
Saude,PERSON
.,O
Braslia,LOCATION
.,O
29,NUMBER
(,O
3,NUMBER
),O
:,O
e2020233,O
.,O
2020,DATE
Betine,PERSON
Pinto,PERSON
Moehlecke,PERSON
Iser,PERSON
et,O
al,O
.,O
28,NUMBER
.,O
Zhang,PERSON
J,PERSON
‐,PERSON
J,PERSON
.,O
Dong,PERSON
X,PERSON
.,O
Cao,O
Y,O
‐,O
Y,O
.,O
Yuan,O
Y,O
‐,O
D,O
.,O
Yang,O
Y,O
‐,O
B,O
.,O
Yan,PERSON
Y,O
‐,O
Q,O
.,O
et,O
al,O
.,O
Clinical,O
characteristics,O
of,O
140,NUMBER
patients,O
infected,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
Allergy,MISC
[,MISC
Internet,MISC
],O
.,O
Forthcoming,O
2020,DATE
Feb,DATE
[,O
cited,O
2020,DATE
Jun,DATE
1,DATE
],O
.,O
29,NUMBER
.,O
Mao,PERSON
L,PERSON
.,O
Wang,PERSON
M,O
.,O
Chen,PERSON
S,PERSON
.,O
He,O
Q,O
.,O
Chang,PERSON
J,PERSON
.,O
Hong,PERSON
C,PERSON
.,O
et,O
al,O
.,O
Neurological,O
manifestations,O
of,O
hospital,O
‐,O
ized,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
in,O
Wuhan,CITY
.,O
China,COUNTRY
:,O
a,O
retrospective,O
case,O
series,O
study,O
.,O
JAMA,MISC
Neurol,MISC
[,MISC
Internet,MISC
],O
.,O
Forthcoming,O
30,NUMBER
.,O
Chen,PERSON
T,PERSON
.,O
Wu,PERSON
D,O
.,O
Chen,PERSON
H,PERSON
.,O
Yan,PERSON
W,PERSON
.,O
Yang,PERSON
D,O
.,O
Chen,PERSON
G,PERSON
.,O
et,O
al,O
.,O
Clinical,O
characteris,O
‐,O
tics,O
of,O
113,NUMBER
deceased,O
patients,O
with,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
:,O
ret,O
‐,O
rospective,O
study,O
.,O
BMJ,O
[,O
Internet,MISC
],O
.,O
2020,DATE
Mar,DATE
[,O
cited,O
2020,DATE
Jun,PERSON
1,NUMBER
],O
;,O
368,NUMBER
:,O
m1091,O
.,O
Approved,O
on,O
26/05/2020,NUMBER
Epidemiol,O
.,O
Serv,O
.,O
Saude,PERSON
.,O
Braslia,PERSON
.,O
29,NUMBER
(,O
3,NUMBER
),O
:,O
e2020233,O
.,O
2020,DATE
